









































effects of immune modulating drugs and HIV on the 
humoral immune response








































Copyright 2010 L.B.S. Gelinck, Leidschendam, The Netherlands.
All rights reserved. No part of this publication may be reproduced in any form or by any 
means, by print, photocopy, scan, electronically or any other means without the permis-
sion of the author.
ISBN 978-90-8559-942-5
Cover: The discarded vaccine syringes for intradermal and intramuscular injection used 
during the conduction of the RICH2 trial (neon adaptation of photograph). Photo & 
design: Luc Gelinck.
Printed by: Optima Grafische Communicatie, Rotterdam, The Netherlands.
The research presented in this thesis was performed at the Department of Infectious 
diseases, Leiden University Medical Center, Leiden, The Netherlands.
The influenzavaccines (used in the studies described in chapter 2-5) were kindly provided 
by Solvay Pharma BV. The research described in Chapter 6 was in part financially sup-
ported by a grant from the Dutch AIDS foundation. 
Financial support for the printing of this thesis was provided by (in alphabetical order): 
Abbott; Boehringer Ingelheim BV; Bristol Myers Squibb; Gilead; GlaxoSmithKline (Viiv); 








































Immunizations in immunocompromised hosts: 




de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof. mr. P.F. van der Heijden,
volgens besluit van het College voor Promoties
te verdedigen op woensdag 17 maart 2010
klokke 16.15 uur
door
Luc Ben Stefan Gelinck














































Prof. dr. T.H.M. Ottenhoff
Prof. dr. C.G.M. Kallenberg (Universitair Medisch Centrum Groningen)








































Quid nobis certius ipsis sensibus esse potest, qui vera ac falsa notemus?
Lucretius (99-55 v. Chr.)
De Rerum Natura (liber primus)
699-700 
What better than the senses can enable us to distinguish the false from the true?
Wat geeft meer zekerheid dan de zintuigen, om onderscheid te maken tussen 
waar en onwaar?
Titus Lucretius Carus, ‘over de natuur der dingen’, eerste boek
Deze zinsnede van Lucretius werd ook door Edward Jenner in 1798 als opdracht opgenomen in zijn werk over 
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In the course of the past centuries vaccination has been proven to be one of the most 
beneficial interventions made in medicine. Vaccination and improved sanitation ended 
the status of infectious diseases as a leading cause of death in many parts of the world, 
thereby saving more lives than any other medical innovation. [1]
Inoculation and variolation were common practice in large parts of the world already 
for centuries, in an attempt to protect people from smallpox. Edward Jenner’s 1798 
publication on variolation however is the first scientific report on vaccination. [2] Some 
80 years later Pasteur published on live attenuated micro-organisms which provided im-
munity against a challenge with virulent micro-organisms, which led to his statement that 
vaccination was now ready for human use. Many disagreed with him on this point, even 
when he successfully vaccinated Joseph Meister, suffering from rabies, with a chemically 
attenuated rabies strain in 1885. The development of safer, killed, vaccines followed shortly 
after these experiments and led to vaccines against Typhoid, Cholera and Plague before 
the beginning of the 20th century. Mass vaccination campaigns held in the British army 
were frustrated by suspicion and emotional opposition, which led to an excess mortality 
of 9000 (unvaccinated) British soldiers due to typhoid fever before the first World War.
Vaccine research flourished in the 20th century: vaccines were developed for more than 
20 pathogens, with a clear decreased circulation of many of those pathogens in the general 
population. Complete eradication of infectious diseases by vaccination has been shown an 
almost impossible quest. The natural circulation of variola, the virus that causes smallpox, 
was interrupted by intensive vaccination campaigns held by the World Health Organisa-
tion (WHO) in 1974. Although efforts to try and eradicate polio are not without success, 
the WHO has had to move the date of expected eradication of this viral disease forward, 
more than once. The fact that the history of vaccination does not only consist of success 
stories is underlined by the difficulties to produce an effective vaccine against the human 
immunodeficiency virus (HIV).
Despite the undisputed merits of vaccination, the negative perception of the general 
public has never completely subsided since the first experiments of Jenner and Pasteur. 
Although there is growing, solid evidence that for instance autism is not caused by the 
vaccine adjuvant thiomersal, some people still refrain their children from vaccination 
because of this fear. [3]
Immunology of vaccination
Although the complexity of the humane immune system was almost completely unre-
vealed in his time, Jenner realized as early as in 1810 that immunity against smallpox was 









































Even now we do not understand all immunological processes involved in the immune 
response upon vaccination in detail. [4] Molecular techniques such as christallography, 
genome wide association scans and cell marker studies did advance our understanding of 
vaccine immunology today. However, in clinical registration trials, it is still the clinical 
endpoint (preventing severe disease or death due to a certain pathogen) that has to prove 
the efficacy of a vaccine.
The immune system is a complex interplay of cellular and soluble factors with the com-
bined ‘goal’ of protecting the host against potentially dangerous factors (such as toxins or 
micro-organisms). Both micro-organisms and the immune system have become extremely 
sophisticated over ages of co-evolution.
Figure 1. shows a schematic, over-simplified, representation of human immunology. 
Mechanic barriers, and processes like mucus, teardrops and urine production, help to pro-
tect humans from exogenous micro-organisms. Once past these barriers, pathogens will 
be recognized immediately by the ‘innate’ immune system, which is able to respond on 
numerous pathogens. Granulocytic cells and inflammatory molecules act synergistically, 
stimulating each other in order to respond to a ‘threat’. This response is rather aspecific and 
can be both local or systemic. Tumor necrosis factor alpha is an important intermediair 
molecule which orchestrates this immune response. There is no immunological memory 
formed upon an innate immune response. This is in contrast with a more specific immune 
response, the adaptive immune response, which is able to form a memory for the antigens 
it encountered, making the response upon a second confrontation with the same antigen 
(booster response) faster, stronger and more specific. The processes involved in forming 
such a booster response are typically T-cell-dependent and include a class switch from IgM 





















































days after re-exposure to the antigen) and avidity maturation (clonal selection of the most 
specific antibodies). An adaptive immune response is initiated only after an antigen is 
processed and presented to T-lymphocytes by antigen-presenting cells. Stimulation of 
the effector cells takes place after specific receptor and co-receptor binding resulting in a 
response for each unique antigen.
The goal of vaccination is to ‘prime’ the immune system for a certain, specific, antigen. The 
immune response upon vaccination typically includes antibody production; most vaccines 
will also induce a T-cell response, leading to a long lasting memory against the pathogen. 
Both antibodies and specific antibody producing B-cell might persist for many decades. [5]
In some cases (e.g. rabies, hepatitis A and B vaccines) immunization will lead to protec-
tive immunity. In other cases (e.g. pneumococcal and influenza vaccines) there will not be 
protective immunity in all who are vaccinated, still the immunity elicited by vaccination 
will most likely mitigate the course of a disease.
Figure 2 depicts the two main routes of antibody production upon vaccination. T-
cell-independent (vaccine) antigens (typically polysaccharides) bind and cross-link B-cell 
antigen receptors, stimulating the B-cell to produce antibodies against this antigen, 
without the formation of memory. T-cell-dependent antigens are processed and presented 
by antigen producing cells, which initiate the immune response. In this thesis we used 
both a T-cell-independent vaccine (polyvalent pneumococcal polysaccharide vaccine) and 












































































The Dutch National Vaccine Program is well embedded in the national healthcare system. 
More than 90 percent of all children are immunized according to a national schedule, 
which is updated regularly. [6] Only a small percentage of children is willingly not vacci-
nated, mostly on religious grounds. Besides vaccines against diphtheria, tetanus, pertusis, 
polio, mumps, measles and rubella the national vaccine program now also includes vac-
cines against Haemophilus influenzae type B, Neisseria meningitides group C, pneumocci 
and human papilloma virus.
Some vaccines, such as hepatitis B, are indicated in selected risk groups only. Influenza 
vaccination is indicated for everybody with an age of 60 years or older; diabetics and 
cardio-pulmonary compromised patients. For patients with an impaired immunity the 
Dutch guidelines state that influenza and pneumococcal vaccination should be consid-
ered. [7,8]
Immunocompromised patients
A growing number of patients lives with an immunodeficiency acquired by disease or 
medical intervention. Several groups of patients, with different mechanisms of the im-
paired immunity, can be identified. Three groups of immunocompromised patients are 
represented in this thesis.
1. Patients treated with immune modulating medication in order to suppress the activity 
of auto-immune disorders.
2. Patients infected with HIV.
3. Patients who underwent a hematological stem cell transplantation, mostly because of 
a hematological malignancy.
These three patient groups represent a wide variety of different mechanisms of immune 
impairment. For some diseases or immune modulating drugs the effect on the immunity 
and more specific the immune response upon vaccination is well characterized. Untreated 
HIV for instance ultimately causes a T-cell deficiency, which can be reversed by adequately 
suppressing HIV replication. The immune deficiency caused by chronic HIV infection 
extends beyond the T-cells and in part also affects humoral immunity.
For new immune modulating drugs, the impact on immunity is often not well charac-
terized. Vaccination studies may help to characterize the immunological consequences of 
drugs like anti-TNF. Comparing the outcomes in the different groups of patients helps to 
weigh the severity of the immunodeficiency.
In this thesis we mainly report antibody responses upon vaccination. By combining the 
use of T-cell-dependent and T-cell-independent vaccines, conclusions can be drawn about 









































Vaccination of immunocompromised patients
Vaccination of immunocompromised patients is more complex than vaccination of 
healthy subjects for several reasons. The immune deficiency places patients more at risk for 
infectious diseases, raising the importance of adequate protection. The goal of protection 
is more difficult to achieve since the immune impairment is likely to interfere with the 
immune response. One of the goals of the studies described in this thesis was to explore 
a strategy (intradermal vaccination) that might increase the response upon vaccination 
in these patients. If patients who do not properly respond upon vaccination are timely 
recognized, alternative measures can be taken for protection.
Studies as described in this thesis increase our understanding of the immunology and 
protection against potentially fatal diseases in those who are the most at risk.
outlIne oF tHe tHesIs
The focus of this thesis is the immune response upon vaccination in immunocompromised 
patients. Three subjects form the core of this thesis.
1. The effect of new immune modulating drugs on the antibody response upon vaccination
The studies described in the first two chapters of this thesis originated from a simple 
question from a clinician who wondered about the immune response upon vaccination in 
a patient treated with anti-TNF. At that time, the spring of 2003, that question proved 
impossible to answer, since no data were published on that subject. To be able to answer 
this question, a clinical trial, with the acronym RICH1 for the immune Response in Im-
munoCompromised Hosts (1), incorporating a T-cell-independent and a T-cell-dependent 
vaccine, was designed. In the study described in chapter 1 the effect of anti-TNF (with 
or without methotrexate) on the response to pneumococcal vaccination is discussed and 
in chapter 2 the effect on influenza vaccination. The appendix to chapter 1 and 2 shows 
data from the RICH1 study that were not published before. Chapter 3 describes the 
effects of another immune modulating agent which is increasingly being used in patients 
failing anti-TNF: rituximab, a B-lymphocyte antagonist.
2. Intradermal vaccination in immunocompromised patients
The chapters 3, 4 and 5 stem from the RICH2 study, which was conducted 2 years after 
the RICH1 study. In the study described in chapter 4 we explored intradermal influenza 
vaccination, to try and improve vaccination outcomes in immunocompromised patients. 
Here too, unpublished additional data, including long-term follow-up data, are included 









































3. Special aspects of the immune response upon vaccination in HIV-infected adults
The study described in chapter 5 explores the ability of immunocompromised patients to 
form broad reacting anti-bodies upon influenza vaccination.
In the study described in chapter 6 a more in depth analysis of several immunologi-
cal aspects of the immune response upon rabies vaccination in HIV-infected patients is 
described. By administering a T-cell-dependent neo antigen in a group of HIV-infected 
individuals with low CD4 nadir counts before the initiation of antiretroviral treatment, 
conclusions can be drawn about the functioning the T-cells that are newly formed in the 
process of immune reconstitution that follows the treatment of HIV. The study cohort 
described in this chapter is unique in the fact that most patients were followed up from 
before the antiretroviral treatment era (allowing for the low CD4 nadir counts) and all 
subjects could be evaluated 5 years after vaccination.
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Introduction. The efficacy of the immune response upon vaccination in patients treated 
with anti-tumor necrosis factor-alpha (anti-TNF) with or without methotrexate is subject 
of debate. We studied the effect of immunosuppressive treatment, including anti-TNF 
and methotrexate, on the response to pneumococcal polysaccharide (PPS) vaccine.
Methods. Fifty two patients treated with immunosuppressives including anti-TNF (anti-
TNF group), 41 patients given a similar immunosuppressive regimen without anti-TNF 
(no anti-TNF group), and 18 healthy controls were vaccinated with a 23 valent PPS 
vaccine. The percentage of patients treated with methotrexate in the anti-TNF and no 
anti-TNF group was 65% and 76% respectively. Antibodies against four of the vaccine 
antigens (PPS 6B, 9V, 19F and 23F) were measured before and four weeks after vac-
cination. The primary outcome was the response rate, defined as the percentage with a 
postvaccination titer ≥ 0.35 μg/ml in combination with at least a two-fold increase in 
antibody titer. The protection rate was defined as a postvaccination titer ≥ 0.35 μg/ml.
Results. The use of methotrexate was the strongest predictor of impaired vaccination 
outcome. Anti-TNF caused an additional immunosuppressive effect in the presence of 
methotrexate, leading to the lowest response percentages in patients using the combination 
of these two drugs. The underlying disease, other immunosuppressives such as prednisone 
or type of anti-TNF agent used did not influence vaccination outcome.
Conclusions. Patients who were treated with the combination of methotrexate and anti-
TNF demonstrated a significantly impaired immune response following pneumococcal 
polysaccharide vaccination as compared to patients treated with either methotrexate or 








































The effect of anti-TNF and methotrexate on PPS23 vaccination 21
IntroductIon
Anti-tumor necrosis factor-alpha treatment (anti-TNF) is effective in the treatment of 
autoimmune disorders like rheumatoid arthritis (RA), ankylosing sponylarthropathy, pso-
riasis and Crohn’s disease. [1,2] A growing number of patients are treated with one of three 
compounds currently registered for clinical usage: infliximab (Remicade™), a chimeric 
monoclonal antibody against TNF, etanercept (Enbrel™), a soluble TNF receptor, and 
adalimumab (Humira™), a humanized monoclonal anti-TNF antibody. [3-6] Although 
highly beneficial in the treatment of these autoimmune diseases, blocking the effects of 
TNF also leads to a specific defect in the cell mediated host immunity, most notably 
leading to severe infections with intracellular micro-organisms, such as tuberculosis. [7-
10] The three available compounds differ in the rate at which complications, such as 
tuberculosis, occur underlining subtle immunological differences in their mode of action. 
[11] Common respiratory tract infections occur 2-4 times more frequent among patients 
treated with anti-TNF and severe bacterial infections, including invasive pneumococcal 
disease, have been reported during anti-TNF treatment. [12-14] Guidelines indicate that 
vaccination with the pneumococcal polysaccharide (PPS) vaccine should be considered in 
rheumatic or inflammatory bowel disease (IBD) patients treated with immunosuppressive 
medication, including anti-TNF. [15-18] The use of immunosuppressives however can 
reduce the response upon vaccination. We reported earlier that anti-TNF has a modest, 
but significant, negative impact on the response to the T-cell-dependent influenza vaccine. 
[19] Other studies reported no significant negative impact of treatment with anti-TNF on 
the response upon the pneumococcal polysaccharide vaccine while some have identified 
methotrexate as an inhibitor of this response. [20-25]
The aim of the present study is to establish the influence of anti-TNF either alone or in 
combination with methotrexate on the antibody response upon vaccination with the 23 
valent pneumococcal polysaccharide vaccine (PPS23).
metHods
Subjects
Patients, 18 years of age or older, treated with anti-TNF at the Leiden University Medi-
cal Center, The Netherlands, were invited to participate in this open-label study, when 
visiting either the rheumatology or gastro-enterology outpatient clinic. Pregnancy and 
an active infectious disease were the only exclusion criteria. From approximately 1000 
patients with Crohn’s disease and 2000 patients with rheumatoid arthritis who visit these 
outpatient clinics a small proportion (<7%, n = 207) was treated with anti-TNF at the 









































were eligible and willing to participate and were enrolled; fifty two patients treated with 
anti-TNF completed both study visits (anti-TNF group). Patients not treated with anti-
TNF were selected from the same outpatient clinics to match those treated with anti-TNF 
for sex, age and immunosuppressive regimen, 54 patients were enrolled, of whom 41 
completed both study visits (no anti-TNF group). Eightteen healthy controls, recruited 
through advertisements, matched for sex and age, completed two study visits.
The main reason for premature drop out from this study was the inability to make extra 
visits because of the distance to the clinic or because of lack of time. None of the subjects 
received prior pneumococcal vaccination.
The protocol was designed according to the good clinical research guidelines and ap-
proved by the medical ethical committee (MEC) of the Leiden University Medical Center 
(local MEC number P03.144) and a written informed consent was provided by all subjects.
Vaccine
The 23 valent pneumococcal polysaccharide (PPS23) vaccine used (0.5 ml Pneumo-23®, 
Merck Sharp and Dohme, Haarlem, The Netherlands) which contained 25 μg of each of 
the following capsular polysaccharides: type 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 
12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F (Danish nomenclature). Vac-
cines were stored at 6°C and administered at room temperature. Vaccinations were given 
according to the package insert by intra-muscular injection in the right deltoid muscle, 
four weeks after an influenza vaccination. Patients registered side effects in a study log.
Antibody assays
Serum samples for determination of pneumococcal antibodies were obtained at the study 
visits at week 0 (before the vaccination) and 4 weeks thereafter and were stored at – 80°C 
until analysis.
Post vaccination IgG antibody levels to four pneumococcal serotypes 6B, 9V, 19F and 
23F were measured by ELISA as described previously. [26] All sera were pre-incubated 
overnight at 4°C with pneumococcal cell wall polysaccharide (CPS) in diluting buffer 
for blocking of non-specific anti-CPS antibodies (50  μg/ml; Statens Serum Institute, 
Copenhagen, Denmark). The pneumococcal antibody reference serum (lot 89-SF) was 
used for assay standardisation.
Primary outcome and statistics
The response rate was defined, in line with World Health Organisation recommendations, 
as the percentage with a postvaccination antibody titer ≥ 0.35 μg/ml in combination with 
at least a two-fold increase in antibody titer. [27] The protection rate was defined as the 
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used, eventhough some polysaccharides are known to illicit better responses than others. 
Geometric mean titers (GMTs) are reported to provide more insight into these differences.
The results were analyzed by one-way ANOVA for GMTs. Response rates were compared 
using Mantel-Haenszel common odds ratio’s and a two-sided χ2-test. A p-value <0.05 was 
considered to indicate a statistical significant difference between groups. A backward step-
wise elimination using a logistic regression model incorporating the variables anti-TNF, 
methotrexate, underlying disease, age and sex was used for analysis. Variables that showed 
no significant impact on vaccination outcomes (the use of prednisone or azathioprine, 
time on anti-TNF, time on immunosuppressive therapy and duration of disease) were not 
further evaluated. Calculations were performed using SPSS for Windows, version 14.0.
results
Baseline characteristics
Ninety-three patients (70% female, mean age 49 years, range 18 - 83) and 18 healthy 
controls (78% female, mean age 47 years, range 21 - 75) were evaluated (table 1). Of 
these 93 patients 80% had a rheumatologic disease (mostly chronic RA) and 20% had 
inflammatory bowel disease (mostly chronic Crohn’s disease) as underlying disease. All 
patients were treated with immunosuppressive drugs such as methotrexate, prednisone 
table 1. Baseline characteristics of study subjects.
characteristics anti-TNF group  
(n = 52)
no anti-TNF group 
(n = 41)
healthy controls  
(n = 18)
P-value
Women (%) 71 68 78 ns *
Age, mean (range), 
years
50 (23 – 73) 47 (18 – 83) 47 (21 – 75) ns †
rheumatic disease 
(%)
88 71 - 0.038 ‡
duration of disease 
activity, mean 
(months)

























* χ2- test (2-sided) for anti-TNF versus no anti-TNF versus healthy controls
† one-way ANOVA for anti-TNF versus no anti-TNF versus healthy controls
‡ χ2- test (2-sided) for anti-TNF versus no anti-TNF
§ Wilcoxon rank sum test (2-sided) for anti-TNF versus no anti-TNF









































or azathioprine; 52 of them (56%) were currently treated with anti-TNF, or had been so 
in the 2 months prior to study entry (anti-TNF group). On average patients had been 
treated with anti-TNF for 23 months (range 1.5 - 79 months). The remaining 41 patients 
received similar immunosuppressive therapy but no anti-TNF (no anti-TNF group) (table 
1). The patient groups did not significantly differ in age, sex, time on treatment or the 
use of immunosuppressive drugs (other than anti-TNF). The percentage of patients with 
rheumatic diseases was significantly higher in the anti-TNF group compared to the no 
anti-TNF group. Within the anti-TNF group all three currently available compounds 
were used, infliximab by 26 patients (50%), etanercept by 10 (19%) and adalimumab by 
16 (31%).
Geometric mean titers
Vaccination resulted in a significant rise of GMTs for all four polysaccharides in all study 
groups. Postvaccination geometric mean titers against the four pneumococcal polysac-
charides did not significantly differ between the three study groups (figure 1).
There was a trend for higher prevaccination titers in the anti-TNF group as compared 
to both the no anti-TNF group and healthy controls.
Response rates
A backward stepwise elimination using a logistic regression model analysis incorporating 
the variables anti-TNF and methotrexate, the interaction of these two drugs, type of anti-
TNF, sex, age and the type of underlying disease (gastro-enterologic vs. rheumatologic) 
was used to control for confounding. The covariates for sex, age, type of anti-TNF and 
type of underlying disease were insignificant and hence removed from the final model 
since only the variables methotrexate, anti-TNF and the interaction of anti-TNF and 
methotrexate were predictors of outcome. Therefore results are presented in a two-by-two 
format based on the use of these two drugs. Adjusted odds ratio’s for the use of anti-TNF 
(vs. no anti-TNF) and methotrexate (vs. no methotrexate) for PPS 6B, 9V and 23F are 
reported in figure 2. For PPS 19F there was a significant interaction between anti-TNF 
and methotrexate, thus separate odds ratio’s within subgroups are reported: the immune 
response in patients using both drugs was significantly inhibited as compared to the use 
of either drug alone (figure 2).
From all immunosuppressives evaluated within this study, the use of methotrexate was 
the strongest predictor of a poor vaccination outcome, reducing the percentage of respond-
ers upon pneumococcal polysaccharide vaccination by four- to eleven-fold, depending on 
the PPS type. A significant inhibiting effect of anti-TNF could only be established in 
patients using methotrexate (PPS 19F). For PPS 9V and 23F the use of anti-TNF reduced 








































The effect of anti-TNF and methotrexate on PPS23 vaccination 25
Although subjects on average did respond to PPS 6B (as measured by increase of GMT 
or the percentage with at least a two-fold titer increase), postvaccination titers were low for 
this polysaccharide. This resulted in response rates ≤11%, which was too low to detect any 
significant inhibiting effect of immunosuppressive medication. Healthy controls yielded 
response rates almost equal to patients not using anti-TNF; patients treated with anti-
TNF showed a trend towards lower response rates compared to patients not treated with 
anti-TNF (table 2).
Protection rates
Although individual cut off values for the separate polysaccharides would probably give 




















































































practice. The general cut off titer of 0.35 μg /ml was easily met by almost all subjects 
for 3 out of 4 antigens, even in patients treated with both anti-TNF and methotrexate 
(100, 94 and 79% for PPS 9V, 19F and 23F respectively). Although these percentages 
were considerably lower for PPS 6B (15% for patients treated with both anti-TNF and 
methotrexate), this percentage was comparable to the other patient groups and healthy 
controls for PPS 6B (table 2).
Adverse events
Mild reactions, such as pain, were frequently reported after vaccination with no differences 
between groups. One 41 year old female RA patient, treated with infliximab combined 
with prednisone, presented herself 48 hours after vaccination with a swelling of the right 
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Figure 2. Response rates, defined as the percentage with a postvaccination titer ≥ 0.35 μg/ml in 
combination with at least a two-fold increase in antibody titer to PPS 6B, 9V, 19F and 23F by use of anti-
TNF (TNF) and methotrexate (MTX): + denotes use, - denotes no use.
Reported are statistically significant (and borderline significant) Mantel-Haenszel common odds ratio’s 
(95% confindence interval) and p-value for anti-TNF vs. no anti-TNF and methotrexate vs. no methotrexate 
(PPS 6B, 9V and 23F).
Because of a statistical significant interaction of methotrexate and anti-TNF the analysis of the effects 
of these drugs on the response upon PPS 19F was analysed in the separate subgroups (no anti-TNF or 
methotrexate, n=18; anti-TNF only, n=10; methotrexate only, n=34; both anti-TNF and methotrexate, 
n=31). The odds ratio’s that were statistically significant are given: * only methotrexate and ** only anti-
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a severe adverse event, however there were no sequellae. She had a remarkable twenty five-
fold increase of antibodies against PPS 9V. No other severe adverse events were reported.
dIscussIon
The main finding of the present study is the synergistic immunosuppressive effect of 
combined methotrexate and anti-TNF use on the antibody response upon pneumococ-
cal polysaccharide vaccination. In patients receiving both drugs response rates were low 
(<30% for PPS 9V and 23F), and even almost absent (3%) for both PPS 6B and 19F. This 
effect was similar with all three currently available anti-TNF agents. Response rates in 
patients not using the combination of anti-TNF and methotrexate (either drug alone or 
other immunosuppressive medication) were comparable to the response rates of healthy 
controls.
Our study consisted of a heterogenic patient group, which mirrors daily practice, how-
ever all clinical variables other than the aforementioned did not significantly influence 
vaccination outcomes. Our findings were consistant for all four polysaccharides tested, 
even though the mean pre- and postvaccination titers differed substantially between these 
four polysaccharides. We believe that individual cut-off levels for the different polysaccha-
rides could be more relevant than a universal cut-off of 0.35 μg/ml as suggested by WHO.
We previously reported a significant inhibiting effect of anti-TNF on the antibody response 
upon influenza vaccination, a T-cell-dependent vaccine. [19] Combined with the type of 
opportunistic diseases seen during treatment with anti-TNF, this led to the hypothesis 
that anti-TNF predominantly influences T-cell-dependent immune responses. Vaccina-
tion with a polysaccharide vaccine is classically considered to be a T-cell-independent 
table 2. The response rate (RR), defined as the percentage with a postvaccination titer ≥ 0.35 μg/ml in 
combination with at least a two-fold increase in antibody titer and the protection rate (PR), defined as the 
percentage with a postvaccination titer ≥ 0.35 μg/ml, per group.
PPS anti-TNF group  
(n = 52)
no anti-TNF group 
(n = 41)











































PPS: pneumococcal polysaccharide; TNF: tumor necrosis factor; ns: not significant









































process, however, our group and others have shown that some of the capsular types (e.g. 
PPS 18C, 19F, 23F) clearly illicit an immune response dependent on the presence and 
functioning of CD4-positive T-lymphocytes (the so called partially T-cell-independent, 
type 2 (TI-2) response), this in contrast with other capsular types (e.g. PPS 1, 4, 6B, 9V, 
14) that act as true T-cell-independent antigens, eliciting a TI-1 response. [28-29] In the 
present study no clear differences between (expected) TI-1 and TI-2 responses could be 
identified, although the only response that was significantly inhibited by anti-TNF (upon 
PPS19F) is partially T-cell-dependent. Another study, which included 7 serotypes in the 
analysis but not PPS 19F found a statistically significant negative impact of anti-TNF on 
the response to the partially T-cell-dependent antigen PPS 23F. [20]
The complexity of the immune system is underscored by the fact that we did not find the 
synergistic effect of methotrexate and anti-TNF when analyzing the immune response 
upon influenza vaccination, within the same cohort. [19] This could also mean that the 
immune suppressive effect of the combination of methotrexate and anti-TNF, also acts 
on processes unique for the T-cell-independent polysaccharides. Some of these B-cell 
specific (T-cell-independent) processes (binding, signaling) have been shown to be TNF 
dependent and might be inhibited by anti-TNF. [30] Combined with the suppression of 
B-cell function and the subsequent inhibition of antibody production by methotrexate, 
this might create a specific B-cell defect, beneficial for the treatment of RA but simultane-
ously leading to impaired immune responses upon polysaccharide exposure. [31, 32] The 
synergistic action of anti-TNF and methotrexate has clearly been established in clinical 
trials assessing different treatment strategies. [33] Further evidence that specific B-cell in-
hibition is relevant in the treatment of RA comes from trials assessing anti-B-cell therapies 
(e.g. rituximab, belimumab as well as sulfasalazine and its metabolites). [34-38]
Several studies, most of which found no immunosuppressive effect of anti-TNF, have 
been conducted in patients with rheumatic diseases. In some of these studies patients were 
vaccinated directly after initiation of anti-TNF treatment, when the immunosuppressive 
effect might not have been fully established. [22-23] Whether or not patients with early 
RA demonstrate the same level of immunosuppression as chronically ill patients is not 
known. [25] The patients in the present study had longstanding disease and were treated 
with anti-TNF on average for almost two years. The trend for higher prevaccination titers 
found in the present study, in patients chronically treated with anti-TNF, might represent 
a higher pneumococcal infection or colonization rate. The percentage of patients who 
were treated for less than three months with anti-TNF in the present study was too small 
to calculate the effect of a shorter exposure to these drugs. Higher prevaccination titers 
did not inhibit the antibody response upon vaccination in the present study, they were 
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A study by Kapetanovic et al., performed in a study population resembling the popula-
tion of the present study, also identified methotrexate as the major inhibitor of the immune 
response upon pneumococcal polysaccharide vaccination. [21] This effect paradoxically 
seemed to be reversed by the use of anti-TNF in their study. Because of differences in 
study design, patient populations and outcome measurements the comparability of the 
present study to other vaccination studies conducted in patients treated with anti-TNF is 
limited. The differences found, stress the need for large, well designed vaccination trials in 
immunocompromised patients.
The true clinical efficacy of pneumococcal vaccination (a reduction of invasive disease 
and mortality attributable to pneumococcal infections) can only be established in trials 
including thousands of participants. Since this is not feasible for patients treated with 
anti-TNF, surrogate markers, such as the response rate, are the best estimate of clinical 
efficacy. The fact that we found blunted response rates in patients treated with the com-
bination of methotrexate and anti-TNF, should not be used to exclude these patients 
from initiatives that promote vaccine uptake in immunocompromised patients. [39-41] 
Even in these ‘worst responders’ we did find antibody titer increases upon vaccination 
and high postvaccination titers, which are also correlated with protection from invasive 
pneumococcal disease. [27] This study was not designed to evaluate the value of routinely 
measuring postvaccination titers in these patients.
We conclude that the response upon the pneumococcal polysaccharide vaccine is sig-
nificantly impaired in patients treated with methotrexate, especially when methotrexate 
is combined with anti-TNF. However, there are no arguments to withhold pneumococcal 
vaccination from this subgroup of patients with combined methotrexate and anti-TNF 
therapy. Ideally, patients should receive pneumococcal vaccination before immunosup-
pressive therapy with methotrexate and/or anti-TNF is initiated or intensified.
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Objectives. The effect of anti-TNF therapy on the antibody responses to vaccines is 
subject of ongoing debate. Therefore, we investigated the effect of the three currently 
available anti-TNF agents on influenza vaccination outcomes in a patient population with 
longstanding disease.
Methods. In a prospective cohort study, we assessed the antibody response upon influenza 
vaccination in 112 patients with longstanding autoimmune disease treated with immu-
nosuppressive medication either with anti-TNF (etanercept, adalimumab or infliximab; 
n=64) or without anti-TNF (n=48) and a control group of 18 healthy individuals. An-
tibody responses were determined by hemagglutination inhibition assay, before and four 
weeks after vaccination.
Results. The proportion of individuals with a protective titer (≥ 40) after vaccination was 
large (80 to 94%) and did not significantly differ between the three groups. Postvaccina-
tion geometric mean antibody titers against influenza (A/H3N2 and B) were significantly 
lower in the 64 patients treated with anti-TNF compared to the 48 patients not receiving 
anti-TNF and the healthy controls.
Conclusions. The antibody response to influenza vaccination in patients treated with 
anti-TNF is only modestly impaired. The proportion of patients that achieves a protective 
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IntroductIon
Anti-tumor necrosis factor alpha treatment (anti-TNF) is effective in autoimmune disor-
ders such as rheumatoid arthritis and Crohn’s disease. [1] The three compounds currently 
registered for clinical use infliximab (Remicade™), etanercept (Enbrel™) and adalimumab 
(Humira™) differ in the mode of action and incidence rate of opportunistic infections. 
[2,3]
Although data on an increased morbidity and mortality due to influenza in patients 
treated with anti-TNF are lacking, guidelines recommend that patients at risk for compli-
cations of influenza, including those treated with anti-TNF, should be annually vaccinated 
against influenza. [4-6] Data on the effect of anti-TNF on the response to influenza vac-
cination are scarce and conflicting. [7-9] The aim of this study is to compare the antibody 
response upon vaccination against influenza in patients treated with immunosuppressive 




Patients, 18 years of age or older, treated with anti-TNF at the Leiden University Medical 
Center, The Netherlands, were invited to participate in this open-label study when visit-
ing either the rheumatology or the gastro-enterology outpatient clinic. Pregnancy, severe 
chicken egg allergy or an active infectious disease were exclusion criteria. Approximately 
1000 patients with Crohn’s disease and 2000 patients with rheumatoid arthritis visit these 
outpatient clinics yearly; 207 patients (<7%) were treated with anti-TNF. Sixty-nine 
(33%) of these patients were enrolled of whom 64 completed the two study visits (anti-
TNF group). Fifty-four patients selected from the same outpatient clinics who were not 
treated with anti-TNF and nineteen healthy controls matched for sex and age were also 
recruited. Respectively 48 (no anti-TNF group) and 18 (healthy controls) also completed 
both study visits. Side effects or worsening of the underlying condition were not stated as 
reasons for study discontinuation by any participant. The protocol was designed according 
to the good clinical research guidelines and approved by the local medical ethical commit-
tee; a written informed consent was obtained from all subjects.
Vaccine
All study subjects were vaccinated in the fall and winter of 2003 with a commercially 
available trivalent subunit influenza vaccine (Influvac™ 2003/2004, Solvay Pharmaceuti-









































of the following strains: A/Moscow/10/99 (H3N2) like strain (A/Panama/2007/99 RES-
VIR-17 reassortant) further referred to as A/H3N2; A/New Caledonia/20/99 (H1N1) like 
strain (A/New Caledonia/20/99 IVR-116 reassortant) further referred to as A/H1N1, and 
B/Hong Kong/330/2001 like strain (B/Shangdong/7/79) further referred to as influenza 
B. Vaccines were stored at 6°C and administered at room temperature by intra-muscular 
injection in the left deltoid muscle according to the package insert. Patients registered side 
effects in a study log.
Antibody assays and statistics
Serum samples were collected at the study visits, at week 0 (before the vaccination) and 
4 weeks thereafter and were stored at – 80°C until use. The hemagglutination inhibition 
(HI) test was performed in duplicate according to standard methods. [10] All sera of each 
individual study subject were tested simultaneously. For statistical analysis a titer of 5 was 
arbitrarily assigned to sera with a titer <10. Protection rates (PR) were defined as the per-
centage of patients with a HI titer ≥ 40 after vaccination, response rates (RR) as a fourfold 
titer increase, in accordance with European guidelines. [11] The results were analyzed 
by standard statistical methods: One-Way ANOVA for geometric mean titers (GMTs), 
two-sided χ2-test for PR and RR. Calculations were performed using SPSS, version 14.0.
results
One hundred and twelve patients (71% female, median age 49 years, range 18 - 85) and 
18 healthy controls (78% female, median age 52 years, range 21 - 75) were evaluated 
(Table 1). The patient groups did not significantly differ in age, sex, time on treatment 
or the use of immunosuppressive drugs (other than anti-TNF) and non-steroidal anti-
inflammatory drugs (NSAIDs). The percentage of patients with rheumatic diseases and 
the percentage of patients who received prior influenza vaccination, in at least one of the 
three years before this study, were significantly higher in the anti-TNF group compared to 
the control patients. Within the anti-TNF group all three currently available compounds 
were used, on average for 24 months (range 0.5 to 78 months): infliximab by 29 (45%), 
including all IBD patients, etanercept by 14 (22%) and adalimumab by 21 (33%).
Four weeks after vaccination against influenza the anti-TNF group had lower GMTs 
when compared to both the no anti-TNF group and healthy controls. This was significant 
for two of the three vaccine components (A/H3N2 and influenza B). The no anti-TNF 
group had insignificantly lower GMTs after vaccination than healthy controls (figure 
1). Response rates were significantly lower in the anti-TNF group compared to the no 
anti-TNF group (p<0.05 for all three antigens). Using slightly different outcome measure-
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table 1. Baseline characteristics of study subjects.
Characteristics Anti-TNF group 
(n = 64)
No anti-TNF 




Women (%) 73 69 78 0.74 a


























Duration of disease activity, mean 
(months)
156 111 - 0.041 d
Prednisone (%) 20 23 - 0.74 c
Mean daily dose, mg 7 9 - 0.58 d
Methotrexate (%) 71 75 - 0.58 c
Mean weekly dose, mg 16 15 - 0.72 d
Azathioprine (%) 8 17 - 0.15 c
Mean daily dose, mg 115 109 - 0.73 d
NSAIDs (%) 57 58 0.90 c
Prior vaccination,% 62 38 6 < 0.001 a
a χ2-square test (2-sided) for anti-TNF versus no anti-TNF versus healthy controls
b One-way ANOVA for anti-TNF versus no anti-TNF versus healthy controls
c χ2-square test (2-sided) for anti-TNF versus no anti-TNF
d Wilcoxon rank sum test (2-sided) for anti-TNF versus no anti-TNF
TNF: tumor necrosis factor alpha; GE: gastro-enterologic; RA: rheumatoid arthritis; JCA: juvenile chronic 









































Figure 1. Crude geometric mean titers (error bars indicate 95% confidence interval) at week 0 and 4 for 
respectively influenza A/H3N2, A/H1N1 and influenza B.
anti-TNF: anti-tumor necrosis factor alpha therapy.









































Protection rates four weeks after vaccination were high in all groups tested (figure 2). 
The percentage with protective titers was 89 – 94% at week 4 in healthy subjects. In 
both patient groups these percentages were slightly lower, with no statistically significant 
differences between the three groups.
Infliximab, etanercept and adalimumab, when tested separately, exert similar effects 
on the response to vaccination. Methotrexate, prednisone, azathioprine and NSAIDs 
did not influence post-vaccination titers significantly when compared to control groups 
(data not shown). Linear regression analysis on post-vaccination titers with age, gender, 
underlying disease, rheumatoid factor positivity, history of previous influenza vaccina-
tions, and prevaccination titers as independent variables, showed that only prevaccination 
antibody titers and a history of previous influenza vaccinations significantly contributed 
to variations in postvaccination titers. Prevaccination titers in healthy controls, resulting 
from natural infection, were higher compared to both patient groups. After correction the 
anti-TNF group still had lower postvaccination titers than the no anti-TNF group.
No major side effects and no deterioration of the underlying condition were attributed 
to influenza vaccination. Minor side effects, such as local pain or tenderness, were fre-
quently reported (20%), with no differences between the three groups. Systemic reactions 
like fever, myalgia or headache were reported in 14% of all patients during the 4 weeks 
after vaccination.
dIscussIon
The present study demonstrates adequate protection rates against influenza after influenza 














































Figure 2. Protection rates before (pre) and 4 weeks after (post) vaccination. P-values from two-sided 
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and lower response rates as compared to both similar patients not treated with anti-TNF 
and healthy controls. To our knowledge this is the first study to include both patients with 
gastro-enterologic and rheumatologic diseases with longstanding auto-immune diseases 
requiring treatment, mirroring daily practice. In the present study all three commercially 
available anti-TNF compounds were used and the average time on this therapy was almost 
two years. In a multivariate analysis, underlying disease (either rheumatologic or IBD), the 
use of methotrexate or the type of anti-TNF compound used (either infliximab, etanercept 
or adalimumab) did not influence vaccination outcomes. Up to now, only a few studies 
have reported on the antibody response upon influenza vaccination in patients treated 
with anti-TNF. [7-9] In line with the current study, these studies agree upon the clinically 
relevant finding that treatment with anti-TNF does not lower the protection rate (table 2).
The seemingly paradoxical finding of significantly lower postvaccination titers (and re-
sponse rates), but equal protection rates, is explained by the fact that the protection threshold 
(a titer ≥ 40) is relatively easily met. Actual postvaccination titers are therefore considered 
a better parameter reflecting the immunological competence of a group. This modest, but 
immunologically relevant, effect was similar for all three antigens and was also consistent in 
various subgroup analyses (RA vs. IBD patients; patients seronegative before vaccination) 
although power was lacking to draw firm conclusions concerning these subgroups.
Two other studies report pre- and post vaccination titers after influenza vaccination in 
patient groups treated with and without anti-TNF. [7,8] In both studies postvaccination 
titers were lower in the group treated with anti-TNF as compared to a control group for 
all three influenza antigens. In the study by Kaine et al. patients received only a single 
dose of adalimumab before vaccination, which might explain the relative modest effect of 
anti-TNF on GMTs in this study (table 2). [7]
Inhibition of TNF, a pivotal cytokine in the type-1 (cell-mediated) immune responses, 
is most noticeable in T-cell mediated reactions. We therefore expected a greater effect of 
anti-TNF on the T-cell-dependent responses to the influenza subunit vaccine as compared 
to the effect on T-cell-independent responses. In most vaccination studies conducted in 
patients treated with anti-TNF, the T-cell-independent pneumococcal polysaccharide 
vaccine was used and, as expected, none of these studies reported a negative impact of 
anti-TNF on vaccination outcomes. [12-15]
In a population consisting of patients with longstanding autoimmune diseases, receiv-
ing immune modulating treatment, the proportion of patients with protective titers after 
a single vaccine dose is substantial, about 80%, irrespective of the immunosuppressive 
medication or underlying condition. This endorses the current guidelines for a single, 









































table 2. Comparison of study outcomes of the publications reporting influenza vaccination results in 
patients treated with anti-TNF. The study outcomes are expressed as percentage higher (+) or lower (-) 
postvaccination outcomes in the different study groups as compared to a reference patient group.












Mixed 64 i/e/a 
(29/14/21)
2 y 65 51 -60 / -35 / -57 -6 / -5 / -9
48 - - 76 47 reference group
HC 18 - - - 47 +25 / +35 / 
+14
+11 / +5 / +1
author 
conclusions
‘significant inhibition of GMTs by anti-TNF, without lowering protection rates’
Kaine 2007
[7]
RA 99 a 1 gift 
(40mg)
56 52 -22 / -14 / -20 -19 (†)
109 - - 54 51 reference group
author 
conclusions
‘adalimumab does not diminish humoral response, the majority of patients are protected’
Kapetanovic
2006 [8]
RA 50 i/e (37/13) 0.7 y 100 53 -42 / -70 / -49 -26 / -42 / -12
62 i/e (27/35) 1.1 y 0 54 +12 / -60 / -39 -3 / -35 / -8
37 - - 100 61 reference group
HC 18 - - - 30 (?) -15 / -31 / -61 -5 / -12 / -29
author 
conclusions
‘immune response sufficiently large, regardless of treatment’
Fomin 2006 
[9]
RA 27 i/e (22/5) >= 3 m 68 59 not reported 
seperately
+31 / +27 / +18 (#1)
55 - - reference group
HC 30 - - - 53 +9 / +9 / +15 +2 / +28 / + 30 (#2)
author 
conclusions
‘infliximab does not affect the humoral response’
(*1) relative percentage higher or lower postvaccination GMTs as compared to reference patient group 
(for respectively influenza A/H3N2, A/H1N1 and influenza B); ‘-70’ indicates a postvaccination titer 70% 
lower than the reference group.
(*2) relative percentage higher or lower protection rate as compared to reference patient group (for 
respectively influenza A/H3N2, A/H1N1 and influenza B), unless stated otherwise; ‘+10’ indicates a 
(relative) 10% higher protection rate as compared to the reference group.
(†) pooled data of 3 antigens (protective antibodies against >= 2 out of 3 influenza antigens)
(?) based on mean age of 47 healthy controls in pneumococcal vaccination study
(#1) difference (%) in percentage of responders (defined as either seroconversion or a fourfold titer 
increase in patients with a protective titer before vaccination) in patients treated with infliximab (n=22) vs. 
no infliximab (n=60, including 5 patients with etanercept)
(#2) difference (%) in percentage of responders (defined as either seroconversion or a fourfold titer 
increase in patients with a protective titer before vaccination) in all patients (n=82) vs. healthy controls 
(n=30)
anti-TNF: anti-tumor necrosis factor alpha therapy; mtx: methotrexate; GMT: geometric mean titer
RA: rheumatoid arthritis; HC: healthy control; i: infliximab; a: adalimumab; e: etanercept;
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Immune Response in Immunocompromised Hosts (rIcH)-1 study – 
additional data
Study scheme
The pneumococcal (chapter 1) and influenza (chapter 2) vaccination (RICH-1) studies 
were done simultaneously within the same study population. The study scheme is rep-
resented in Figure 1: patients received an influenza vaccination at week 0, with a second 
influenza vaccination at week four, to study if this would increase the number of subjects 
with a protective titer. At week 4 a pneumococcal vaccination was administered simultane-




    
    
   
        
Figure 1. Flowchart with a schematic representation of the RICH-1 study, including the number of 
participants at the different time points.
The number of patients lost-to-follow up was high in this study, increasing with every 
study visit. An important reason for this was that anti-TNF was not readily available in 
2003. Anti-TNF was used in clinical trials as a rescue treatment for patients failing other 
drug regimens. Many patients travelled long distance to be included in these treatment 
trials, the travel associated with the extra visits for the vaccination study proved to be 
problematic for some of the patients.
Follow up
that completed all three study visits, revaccination did not give rise to a booster response 
(Figure 2); only a modest increase of patients with a protective titer was seen (Figure 3). 
Thus, repeated influenza vaccination with only a four week interval does not provide a 
relevant increase of anti-influenza The influenza follow-up data are presented in Figure 2 
and 3. Within the group of patients immunity.
Evaluation of different immunological pathways
As described in de general discussion of this thesis, evaluating both a T-cell-dependent 
(influenza) and T-cell-independent (pneumococcal) vaccine, within the same patient 
cohort gave us the opportunity to study the immunological properties of anti-TNF alone 
and in combination with other drugs. Table 1 shows correlations between the response 









































pneumococcal antigens (the response rate as defined in chapter 1). The strength of the 
correlation is coded by the colour of the cells, p-values are coded by asterixes. As would 
be expected, there are clear correlations among the influenza antigens on one hand and 
pneumococcal antigens on the other hand. There is, however, a striking absence of correla-
tions between the response upon influenza and pneumococcal antigens. Most correlations 
found were weak (Pearson’s correlation coefficient <0.5), only responses upon the two 
influenza A strains (H3N2 and H1N1) and the responses upon PPS 19F and two of the 
other PPSs showed stronger correlations. The fact that the responders upon influenza vac-
cination and the responders upon pneumococcal vaccination do not correspond with each 


























Figure 2. Geometric mean titers (95% confidence interval) against influenza A/H3N2, A/H1N1 and 















































Figure 3. Protection rates (the percentage of subjects with a titer >40) at week 0 (prevaccination), 4 and 8 
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In conclusion repeated influenza vaccination with only a four week interval does not 
provide a relevant increase of anti-influenza immunity. Influenza and pneumococcal vac-
cination respectively evaluate T-cell-dependent and T-cell-independent pathways.
table 1. Cross tabulation, indicating positive correlations for responders upon influenza and PPS antigens.




















TNF- * * **
TNF+ ** *
Pearson’s correlation coefficient: white < 0.3; grey 0.3-0.5; black >0.5
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Objectives. We examined the impact of rituximab on influenza vaccination outcomes in 
rheumatoid arthritis (RA) patients.
Methods. Four RA patients treated with Rituximab, 25 RA patients treated with anti-tu-
mor necrosis factor alpha (TNF), and 20 healthy controls, were vaccinated with a trivalent 
influenza vaccine. Hemagglutination inhibition (HI) titers were measured to determine 
the response upon vaccination.
Results. Significantly lower postvaccination titers were found in the RA patients treated 
with rituximab, compared to both control groups.
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IntroductIon
Annual influenza vaccination is recommended for immunocompromised patients at the 
beginning of each winter season, under the assumption that it will provide protection 
against the circulating viral strains during the influenza season. [1,2] Rituximab, an anti-
CD20 monoclonal antibody which was recently approved by American and European 
authorities for the treatment of RA patients failing anti-TNF, diminishes circulating 
B-cells for a period of 6 to 9 months after infusion .[3-5] The package insert states that 
patients should not be vaccinated from 1 month before administration of rituximab until 
6 months thereafter based on data in lymphoma patients.[6-8] In these studies rituximab 
influenced primary as well as secondary immune responses to neoantigens (keyhole limpet 
hemocyanin and hepatitis A vaccine) and recall antigens (tetanus toxoid and poliomyelitis 
vaccine). [7] Certainly the underlying lymphoma and treatment with chemotherapy 
contributed to the diminished immunological responses in these patients. The effect of 
rituximab on influenza vaccination outcomes in RA, therefore, is not known.
metHods
We examined the humoral responses upon influenza vaccination in four RA patients (3/4 
female, age range 55-61) all treated with rituximab combined with methotrexate (5-20 
mg weekly) and prednisone (5 mg) in one patient and compared these to responses of 25 
patients treated with anti-TNF with or without disease modifying anti-rheumatic drugs 
(DMARDs; 64% female, mean age 54 years, range 37-71), and 20 healthy controls (50% 
female, mean age 45 years, range 19-77). The four patients received 1000 mg rituximab 
intravenously on days 0 and 14. Infusions were combined with 100 mg prednisolone and 
2 mg clemastine. A timeline summarizing these events, as well as the waning of B-cell 
counts after rituximab infusion in the four individual patients, is presented in figure 1.
Patients were vaccinated intramuscularly, as part of a larger study, with a trivalent 
subunit vaccine (Influvac 2005-2006, Solvay, Weesp, The Netherlands; 0.5 mL contain-
ing 15 μg hemagglutinin of each of the following strains: A/California/7/04 like virus 
(further referred to as A/H3N2), A/New Caledonia/20/99 like virus (further referred to 
as A/H1N1) and B/Shanghai/361/02 like virus (further referred to as influenza B). The 
influenza vaccine was administered between 87 – 140 days after the first rituximab infu-
sion (figure 1). HI titers were measured (in duplo) just before vaccination and 28 days 
later as described before. [9,10] We report (geometric) mean titers (GMTs) as our main 
outcome to compare groups. [11] Protection rates (the percentage of a group with a titer ≥ 
40, which is considered to be protective) were calculated. For B-cell counts blood samples 









































B-lymphocytes were identified using a 4-color stain-lyse-no wash platform method, using 
incubation with a mixture of monoclonal antibodies against CD45 (clone 2d-1), CD3 
(clone SK-7) and CD19 (clone 5J25C1)(BD biosciences, San Jose, CA, USA). Absolute 
lymphocyte counts were analyzed by TruCOUNT tubes using flowcytometry. The lower 
limit of detection for B-cells was 1 x106 cells per L. Pearson’s chi-square test and ANOVA 
statistics were used where applicable.
results
The 4 RA patients treated with rituximab had significantly lower postvaccination titers 
compared to both control groups (RA patients treated with anti-TNF with or without 
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Figure 1. Graphical representation of rituximab (RTX) infusions, the period in which the influenza vaccine 












































Figure 2. Pre- and postvaccination serum geometric mean titers (GMT with standard deviation) against 
influenza A/H3N2, A/H1N1 and Influenza B for a group of RA patients treated with rituximab (RA - RTX), RA 
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also were significantly lower in the rituximab group (25-50%) compared to both control 
groups (84% for all three antigens in the RA group and 85-100% in healthy controls, p 
< 0.05 for all three antigens with Pearson’s chi-square test). The three groups were well 
matched with regard to sex, age, prevaccination titers and prior influenza vaccination. 
B-cells were completely depleted in all four patients at day 84 after the first rituximab 
infusion. Only one patient had complete B-cell recovery at day 168. This patient was 
vaccinated 3 days after the nadir measurement (day 84: 1 x106/L). No major side effects 
were observed after vaccination nor any effect on disease activity.
dIscussIon
Even though only four RA patients treated with rituximab were evaluated, we found sig-
nificantly lower postvaccination titers (figure 1) and protection rates (the proportion of a 
group with a titer ≥ 40) in comparison to compared to a group of RA patients treated with 
anti-TNF and a group of healthy controls for all three antigens. The influenza vaccine was 
administered 3 to 5 months after the first rituximab infusion at the time of early B cell 
recovery (<10 x106 CD19+ cells/L in blood). In keeping with previous studies, influenza 
vaccination was effective in RA patients treated with anti-TNF, although the induced 
concentrations of antibodies against the three antigens were slightly lower than in healthy 
controls. [12,13] Thus, the impaired effectiveness in rituximab treated RA patients cannot 
be explained by the presence of underlying disease or the use of other immunosuppressive 
medication. One other study reported a significantly lower response rate for only one out 
of three antigens in RA patients treated with rituximab. [14] The comparability to our 
results is limited since responses were poor in all groups and no information was provided 
on rituximab dose and number of B-cells at time of vaccination.
In conclusion, our findings suggest that influenza vaccination, although not completely 
ineffective, will most likely not sufficiently protect rituximab treated RA patients from 
influenza infection during the whole winter season. Other preventive strategies and pre-
cautions, such as vaccinating household members and pre-emptive or early treatment with 
anti-viral medication after exposure, should also be considered.
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Background. Many strategies, including intradermal vaccination, have been tested to 
augment antibody responses upon vaccination. This strategy has not been evaluated in dif-
ferent groups of immunocompromised patients. We conducted a prospective, randomized 
study to compare the humoral response upon standard intramuscular influenza vaccina-
tion with the response upon reduced-dose intradermal vaccination in patients treated with 
anti-tumor necrosis factor (TNF)-alpha, human immunodeficiency virus (HIV)-infected 
patients, hematologic stem cell transplantation (HSCT) patients, and healthy controls.
Methods. In total 156 immunocompromised patients and 41 healthy controls were 
randomized to receive either 0.5 mL of the 2005/2006 trivalent influenza vaccine intra-
muscular or 0.1 mL intradermal. Humoral responses, determined by hemagglutination 
inhibition assay, were measured before and 28 days post vaccination. Geometric mean 
titers (GMTs) and protection rates (PRs) are reported as primary outcomes, adverse events 
as a secondary outcome.
Results. Reduced-dose intradermal vaccination leads to similar GMTs and PRs, within 
all tested groups, compared to the standard intramuscular vaccination. Healthy controls 
yielded significantly better GMTs and PRs than immunocompromised patients. Local 
skin reactions after intradermal vaccination occurred less frequent and were milder in 
immunocompromised patients than in healthy subjects and were predictive for a positive 
vaccination outcome for individual subjects.
Conclusions. Intradermal influenza vaccination is a feasible alternative for standard 
intramuscular vaccination in several groups of immunocompromised patients, including 
those treated with anti-TNF, HIV-infected patients and HSCT patients. The occurrence 
of a local skin reaction after intradermal vaccination is predictive of a response to at least 
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backGround
Annual influenza vaccination is recommended for immunocompromised patients. [1-4] 
Besides causing a greater risk of complications from influenza infection, an immunode-
ficiency compromises the response to (T-cell-dependent) vaccine antigens. [5-7] Many 
strategies have been explored in immunocompromised patients in order to optimize 
vaccination outcomes, including increased dosage, multiple dose vaccination, the use of 
vaccine adjuvant, immunostimulant patches and more efficient routes of vaccine delivery. 
[8-12]
In persons with impaired immunity intradermal vaccination is of particular interest 
because of anticipated immunologic advantages. The dermis harbours a network of an-
tigen presenting cells, constituting up to two percent of all dermal cells, which forms an 
optimal environment to deliver a vaccine. [13-15] Since there is a dose-response relation 
for antigen quantity and antibody response, studies in immunocompromised patients have 
mostly concentrated on higher vaccine doses administered intramuscularly. [6, 16] The 
favourable immunologic properties of the dermis allow for smaller quantities of vaccine 
to be used. Healthy subjects respond to reduced-dose intradermal influenza vaccination 
generally just as well as to standard intramuscular vaccination, especially in populations 
already primed with the antigen. [17-26] Intradermal influenza vaccination received most 
attention in times of vaccine shortage caused by pandemics (e.g. the 1957 influenza A/
H2N2 pandemic) or manufacturing problems as occurred in 1973 and 2004. [27, 28] 
These studies concentrated on the responses of healthy subjects. Only little information 
is available on intradermal influenza vaccination in immunocompromised patients. [29]
Besides a potential immunologic benefit, there is an obvious economic advantage in 
saving up to 80% of the vaccine required, allowing for full vaccination coverage even 
in times of vaccine shortages. [30-31] There are however also some inherent practical 
disadvantages to intradermal vaccination, especially relevant in mass vaccination cam-
paigns such as the annual influenza vaccination campaigns or the response to an eventual 
pandemic influenza outbreak. The vaccination technique itself is more difficult and time 
consuming than intramuscular vaccination. Furthermore, local side effects in healthy 
subjects, are more severe and frequent upon intradermal vaccination when compared to 
intramuscular vaccination, a factor known to negatively impact vaccine uptake. [32-33] 
These factors and the small number of data on intradermal vaccination in subjects with an 
indication for annual influenza vaccination have likely contributed to the decision from 
the Center of Disease Control and Prevention (CDC) to discourage intradermal influenza 
vaccination in its 2007 guidelines, especially for persons older than sixty years. [1]
Before intradermal influenza vaccination can be implemented as a routine procedure, 
the efficacy and safety should be established in patient groups with an indication for 









































hypothesis whether reduced-dose intradermal influenza vaccination in immunocompro-
mised patients, in particular those treated with anti-tumor necrosis factor (TNF) alpha, 
persons infected with the humane immunodeficiency virus (HIV) and patients who have 
undergone hematological stem cell transplantation (HSCT), is safe and whether it leads 
to an equal quantitative serologic response as compared to the response upon standard 
intramuscular vaccination.
metHods
Trial design and subjects
A group of healthy controls (HC group) and three groups of immunocompromised pa-
tients were included in this trial. Rheumatologic patients treated with anti-TNF with or 
without other immunosuppressives at the Leiden University Medical Center (LUMC), 
Leiden or the Sint Maartenskliniek, Nijmegen, The Netherlands (anti-TNF group); HIV 
infected patients in care at the LUMC (HIV group) and HSCT patients treated at the 
LUMC (HSCT group) were asked to participate.
Importantly, this study was designed to mirror clinical practice, with few limitations 
for inclusion. Exclusion criteria included only known allergy to influenza vaccine, severe 
chicken egg allergy, age below 18 years, the use of oral anticoagulation therapy, a throm-
bocyte count less than 25 x 109 per liter and a skin type not suitable for intradermal 
vaccine delivery (such as severe corticosteroid-induced skin atrophy). The four study 
groups were randomized to receive either standard intramuscular vaccination or reduced 
dose intradermal vaccination. Permuted-block randomization was performed with the 
use of sealed envelopes containing the balanced vaccination codes for ten subjects. All 
subjects were asked to register adverse reactions in a study log. The study protocol was 
approved by the appropriate institutional ethics committees (LUMC, local CME number 
P05.115; Sint Maartenskliniek local CME number RR-14-GRIEP; ISRCTN15762138) 
and conducted in accordance with de Declaration of Helsinki. All participants provided a 
written informed consent.
Vaccine and vaccination
All study subjects were vaccinated in the fall and winter of 2005 with a commercially avail-
able trivalent subunit influenza vaccine (Influvac™ 2005/2006, Solvay Pharmaceuticals 
B.V., Weesp, The Netherlands) at day 0. The vaccine contained 15 μg of hemagglutinin of 
each of the following strains: A/California/7/04 (H3N2) like strain (A/New York/55/2004 
NYMC X-157 reassortant) further referred to as A/H3N2; A/New Caledonia/20/99 
(H1N1) like strain (A/New Caledonia/20/99 IVR-116 reassortant) further referred to 
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influenza B. The A/H3N2 was the only new strain in this vaccine: the A/H1N1 vaccine 
strain remained unchanged since the season of 2000/2001; the influenza B strain was 
identical to the strain used in 2004/2005.
Vaccines were stored at 6°C and administered at room temperature. Intramuscular 
vaccinations (0.5 mL) were given according to the package insert by injection in the left 
deltoid muscle. On a daily base vaccine for the intradermal administration was transferred 
from the pre-filled vaccination syringe into sterile vials and 0.1 mL of vaccine fluid, 
containing 3 μg of hemagglutinin of the three strains, was then delivered intradermal in 
the palmar side of the forearm according to the CDC guidelines using an intradermal 
injection syringe (BD Micro-Fine 0.5 mL U-100 insulin syringe) and needle (29G), also 
used for intradermal tuberculin injections. [34] All vaccines were administered by the 
investigators who were trained in both vaccination techniques. Directly after vaccination 
wheals were measured to confirm adequate intradermal vaccine delivery.
Antibody assays and statistics
Serum samples were collected at day 0 (before vaccination) and day 28 and were stored at 
–80°C until use. The hemagglutination inhibition (HI) test was performed in duplicate 
according to standard methods with turkey erythrocytes and four hemagglutinating units 
of virus to measure antibodies against each of the three vaccine strains as described before. 
[5] Ferret sera raised against the test antigens were used as positive controls. All sera of 
each individual study subject were tested simultaneously. For statistical analysis a titer of 
5 was arbitrarily assigned to sera with a titer <10. Titers were transformed to a logarithmic 
scale and geometric means were used for further calculations. Geometric mean titers are 
the strongest markers of the immunological capability of a group to respond to an antigen 
and were therefore preferred over the response rate (fourfold titer increase), or other out-
come measurements that depend heavily on prevaccination titers. Protection rates (PR) 
were defined as the percentage of patients with a HI titer ≥ 40, which is considered to be a 
clinically relevant titer, known to be associated with protection against severe influenza in 
healthy controls, after vaccination. [5, 35] The results were analyzed by one-way ANOVA 
for geometric mean titers (GMTs), two-sided χ2-test for PR.
Multivariate analysis of postvaccination GMTs, using a logistic regression model in-
cluding the variables age, sex, previous vaccination, prevaccination titer and vaccination 
route was performed on the four different study groups. Group specific variables were 
added to the model were applicable (DAS28, type of anti-TNF, use of methotrexate in 
the anti-TNF group; a CD4-count of less than 200 cells per mm3, CD4 nadir, the use of 
HAART in the HIV group; type of transplantation and being within the first year post 
transplantation in the HSCT group).
A p-value <0.05 was considered to indicate a statistical significant difference between 











































Baseline characteristics of the 197 participants who were randomized are summarized in 
Table 1. The 41 healthy controls included many healthy partners of patients and hospital 
staff. The hospital endorses an active policy of influenza vaccination, explaining the relatively 
high percentage that received a prior influenza vaccination. Fifty patients treated with anti-
TNF (fourty RA patients, six with spondyloarthropathy, three with psoriatic arthritis and 
one with juvenile chronic arthritis) were well matched with regard to gender, age, percentage 
of patients with RA, disease activity score (DAS28), type of anti-TNF used (two-third were 
treated with etanercept, one sixth each with infliximab and adalimumab) and other im-
munosuppressives (methotrexate was used by 28% of the patients and prednisone by 12%). 
The percentage of study subjects in the anti-TNF group vaccinated in previous influenza 
seasons was almost twice as high in the intradermal group as compared to the intramuscular 
group (p=0.08). A DAS28 of 3.7 represents a moderately severe disease activity.
Eighty HIV infected patients were well matched with regard to gender, age, prior 
influenza vaccinations, actual CD4 count and time on antiretroviral therapy. Over 80% 
of patients were treated with antiretroviral therapy, the mean time on therapy exceeded 
five years. The mean CD4 nadir was 166 and 193 cells/mm3 in the intramuscular and 
intradermal arm respectively. Only 10 patients with a CD4 count of <200 cells / mm3 
were included.
table 1. Baseline characteristics of subjects.
characteristics HCs anti-TNF HIV HSCT p-value
vaccination route im id im id im id im id
n 20 21 25 25 41 39 13 13






















25 48 28 52 61 59 46* 46* ns
DAS28, mean - - 4.0 3.1 - - - - ns
CD4, mean, cells/mm3
(range)







time since hsct , 
months (range)





* percentage denotes vaccination status of subjects, not of donors (in case of allograft transplantation)
χ-square test (2-sided) for intramuscular versus intradermal in the four study groups
one-way ANOVA for intramuscular versus intradermal in the four study groups
HCs: healthy controls; TNF: tumor necrosis factor; HIV: human immunodeficiency virus; HSCT: hematologic 
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Twenty-six HSCT patients were well matched in regard to gender, age, prior influenza 
vaccination and time since transplantation. Underlying diseases were multiple myeloma 
(n=10), acute myeloid leukaemia (n=7), non-Hodgkin lymphoma (n=3) and other (n=6). 
The intradermal group had a higher percentage of patients with an allograft (62 vs 23%, 
p=0.047).
Immune responses
The intradermal vaccination with a low dose resulted in similar postvaccination titers as 
compared to standard intramuscular vaccination in all four study groups (HC, anti-TNF, 
HIV and HSCT group). There was a clear hierarchy in postvaccination titers and protec-
tion rates for the different study groups (in both intramuscular and intradermal study 
arms): healthy controls showed the best responses followed by the anti-TNF group, the 
HIV group and the HSCT group respectively (Figure 1). Multivariate analyses were done 
in the four separate study groups.
Prevaccination titers were already protective for a considerable percentage of the sub-
jects (figure 2), which can be caused by either natural exposure or previous vaccination.
The correlation between previous vaccination and higher prevaccination titers was 
the strongest for the two antigens that were identical to the ones used in the previous 
(2004/2005) vaccine: influenza A/H1N1 and B (data not shown). Higher prevaccination 
titers were associated with higher postvaccination titers in all study groups.
In the HIV group, older age and a CD4-count of less than 200 cells per mm3 were 
associated with lower postvaccination GMTs when controlling for sex, HIV treatment, 
previous vaccination and prevaccination titers.
In the HSCT group, no prior vaccination and being within the first year post trans-
plantation were associated with lower postvaccination titers (allotransplantation vs. 
autotransplantation only showed a trend for lower postvaccination titers). For healthy 









































Figure 1. Geometric mean titers at day 28 for respectively influenza A/H3N2, A/H1N1 and influenza B. 
Error bars indicate 95% confidence interval.
HC: healthy control; TNF: tumor necrosis factor; HIV: human immunodeficiency virus; HSCT: hematologic 
stem cell transplantation; im: intramuscular; id: intradermal









































controls and the anti-TNF group there were no additional factors associated with lower 
postvaccination titers.
In concordance with the postvaccination titers, the protection rates were similar after 
intradermal and intramuscular vaccination in the four study groups, for all three antigens. 
As depicted in Figure 2, the highest percentages of protective titers were seen in healthy 
controls (81-100%, depending on vaccination route and antigen). Protection rates were 
lower in anti-TNF and HIV patients (66-84%) and lowest in HSCT patients (23-62%).
All of the healthy controls responded to at least one antigen and 76% to all three 
antigens contained in the vaccine (Figure 3). In contrast, 42% of all HSCT patients did 
not respond to any antigen and only 27% responded to all three. Data for the other study 
groups are depicted in Figure 3.
In a subgroup analysis of patients with the most severe immunodeficiencies, consisting 






























































































































































































































































































Figure 2. Protection rates before (pre) and 28 days after (post) vaccination for respectively influenza A/
H3N2, A/H1N1 and influenza B. P-values from two-sided Pearson’s χ2-test between groups.
HC: healthy controls; TNF: tumor necrosis factor; HIV: human immunodeficiency virus; HSCT: hematologic 
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within the first 11 months following transplantation (n=11), the antibody responses were 
very poor (postvaccination GMTs of 21, 26 and 13 for respectively A/H3N2, A/H1N1 
and influenza B). Of the 21 patients, 6 were vaccinated before and received intradermal 
vaccination. These six patients yielded remarkable protection rates for patients with a 
severe immunodeficiency (67-83% (depending on the antigen) vs. 13-27% in the 15 
patients not vaccinated before and/or vaccinated intramuscular, p< 0.05 for A/H3N2 and 
influenza B; p=0.09 for A/H1N1).
Safety and adverse reactions
The mean diameter of the wheal caused by the intradermal vaccination was 7.6 mm (SD 
1.6 mm), with no significant differences between the study groups. Skin atrophy caused 
by corticosteroid use in the past and a very dark skin colour made the technique of intra-
dermal vaccine delivery more difficult.
To exclude a recall bias, only study logs that were returned within three months after 
vaccination were included in the safety analysis. Sixty three percent of the participants 
(n=125) returned the study log and recorded whether or not they had suffered adverse 
reactions.
No serious adverse reactions were experienced in the present study. The frequency of 
adverse reactions after intramuscular vaccination (ranging from muscle pain to fever) 
reported in this study was high (11-48%). Local reactions, mostly consisting of a transient 
painless erythema, 48 hours after intradermal vaccination, occurred frequently in the 
intradermal groups, however significant more often in healthy controls than in immu-
nocompromised patients (p<0.05 Pearsons chi square test, Table 2). The frequency of 



































Figure 3. Percentage with a protective titer (≥40) against either 0, 1, 2 or 3 of the three vaccine 
(hemagglutinin) antigens for the different study groups.
HC: healthy controls; TNF: tumor necrosis factor; HIV: human immunodeficiency virus; HSCT: hematologic 









































vaccination and was the highest in healthy controls, followed by the anti-TNF group, 
HIV group and HSCT group respectively (Table 2).
Of the subjects who did not respond to any of the antigens after intradermal vaccina-
tion, only one subject reported a local skin reaction. In contrast, all healthy controls (and 
69% of immunocompromised patients) who responded to all three antigens reported a 
local skin reaction. Local skin reactions were predictive of a response to at least one out of 
three antigens (paired samples t-test, p<0.05), with a sensitivity of 63% and a specificity 
of 83% for all subjects pooled.
dIscussIon
Intradermal influenza vaccination, using only a fifth of the normal dose, leads to similar 
postvaccination antibody titers and protection rates as compared to standard intramuscular 
vaccination in immunocompromised patients. Since there is a dose-response relation be-
tween the amount of antigen used and the subsequent serologic response, this indicates that 
intradermal vaccination is more efficient in inducing antibody responses than intramuscular 
vaccination. [17, 18] This principle was recently proven to be valid in a clinical study. [36]
A likely mechanism for this phenomena is that the abundance of antigen presenting 
cells (APCs) in the dermis reduces the chance that antigens are cleared by circulating 
pre-existing antibodies or non-specific immunity after intradermal vaccination. In animal 
studies, intradermal vaccination induced a faster and more profound cellular immune re-
sponses in the local lymph node than intramuscular vaccination. [37] Earlier studies that 
compared reduced dose intradermal influenza vaccination with standard intramuscular 
vaccination have been criticized for not including a third study arm with a low dose (0.1 
mL) delivered intramuscular. [38] Since we anticipated significantly lower protection rates 
in patients indicated to receive influenza vaccination, such a study arm was not considered 
to be ethical. [16]
table 2. Percentage of subjects that reported side effects following vaccination within each study group. 
P-values from comparison against healthy controls (Pearson chi-square test).
study group im p-value id p-value
HCs 18 reference 89 reference
anti-TNF 48 ns 58 ns
HIV 19 ns 55 ns
HSCT 11 ns 25 .01
ICHs
(total of three patient groups)
30 ns 52 .038
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Patients who, as a result of cellular immunodeficiency, respond with lower postvaccina-
tion titers and protection rates to T-cell-dependent vaccines such as the influenza vaccine 
have the most to gain from a more efficient immune response. [5-7] The underlying T-cell 
and APC defects, different in nature and severity in the three patient groups of the pres-
ent study, can be partially overcome by using intradermal vaccine delivery. [39-41] In 
the present study, only the HIV-group had higher titers after intradermal vaccination. 
Whether or not this reflects a true different (more efficient) mechanism as opposed to 
the other study groups is not clear from the present study. The only other study that 
reported on intradermal influenza vaccination in HIV-infected patients also found a trend 
for a higher percentage of responders in subjects receiving intradermal vaccination than in 
those receiving standard intramuscular vaccination. [29]
Several vaccines have been proven to be safe and effective when a reduced dose was 
delivered intradermally, mostly in immunocompetent subjects. [42-46] Intradermal 
vaccination in immunocompromised patients has been studied extensively, mostly using 
the hepatitis B virus (HBV) vaccine. A meta-analysis of intradermal HBV vaccination 
in patients with chronic kidney disease showed higher protection rates after intradermal 
administration of the vaccine than after standard intramuscular vaccinations. This differ-
ence was no longer detected during the follow up (6-60 months after completion of the 
vaccination schedule). [42]
Although in theory intra-dermal delivery of vaccines could save up to 240 million of 
the 300 million influenza vaccine doses distributed annually worldwide, this is not likely 
to be a realistic scenario. [31] The more demanding administration technique will hamper 
mass vaccination campaigns and the frequency and severity of adverse effects following 
intradermal vaccination in immunocompetent subjects are such that this technique is 
unsuitable for routine influenza vaccination. Immunocompromised patients, however, 
form a relatively small subgroup of those indicated for annual influenza vaccination and 
adverse reactions are significantly milder and less frequent in these patients than in healthy 
subjects. The overall frequency of adverse reactions might be overestimated in the present 
study, since a proportion of the subjects who did not return their study log, reported that 
they did so because they had no adverse events to report.
An interesting finding in the present study was that the presence of a local skin reaction 
correlated with the magnitude of the antibody response to at least one out of the three 
vaccine antigens. The absence of a local skin reaction within the first 48 hours following 
vaccination identified patients that did not develop an adequate response (measured 4 
weeks later). In our study this subgroup was too small to evaluate the effect of booster 
vaccination. The skin reaction was interpreted as a delayed type hypersensitivity reaction, 
which could be directed at either of the three hemagglutinin or neuraminidase antigens or 









































Of further interest were the remarkably high postvaccination protection rates after 
intradermal vaccination in a subset of severely immunocompromised patients who were 
vaccinated before. A greater effect of intradermal vaccination in a primed population 
as compared to a ‘virgin’ population was already reported 50 years ago. [20] Again the 
subset of (combined HIV and HSCT) patients was too small in the present study to draw 
any firm conclusions. Still, the fact that up to 83% of the primed patients who received 
intradermal vaccination, had protective postvaccination titers suggests that intradermal 
vaccination could be the most optimal route of (annual) vaccination in patients with a 
severely impaired cellular immunity.
In conclusion, dose sparing intradermal influenza vaccination is a feasible alternative 
for the routine practice of intramuscular vaccination in several groups of immunocom-
promised subjects, including patients treated with anti-TNF, HIV-infected patients and 
HSCT patients. In these patients the local skin reaction upon vaccination may be used 
as a predictor for the outcome of vaccination, identifying the patients who most likely 
would benefit from a booster vaccination. Intradermal vaccine delivery should be further 
explored, especially for annual influenza vaccination of severely immunocompromised 
patients.
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Background
The original study protocol included a cross-over design with an influenza re-vaccination 
at week 4. The reason for this re-vaccination was to minimize the risk of underprotection 
in immunocompromised patients, who received a reduced dose vaccination. The reason 
to re-vaccinate already at week 4 was mostly practical: in the RICH-1 study the number 
of patients lost to follow up increased with every time point, further more we aimed to 
achieve maximal protection in time for the influenza season.
Wheal size, side effects and immune response
As a quality control wheal size was measured after every intradermal vaccination (Figure 
1a). A wheal size of greater than or equal to 6 mm was considered adequate. This was 
achieved in all but 3 subjects (Figure 1b). The final analysis was done on a intention-to-
treat base, however excluding these three subjects from the analysis did not alter outcomes. 
Unfortunately, we did not systematically ask subjects to measure the size of the postvac-
cination skin rash. Especially in healthy controls, a local reaction of more than 5 cm 
in diameter was frequently noticed (Figure 1c). As noted in the article, frequency and 










Figure 1a. Typical wheel (diameter 8 mm) after intradermal vaccination in a HIV-infected patient with 
lipo-atrophy. 1b. Histogram of wheel size in all subjects. 1c. Painless local skin reaction (maximum 









































severity of the local skin reaction was related both to the severity of the immunodeficiency 
and the subsequent antibody response.
Longterm follow up
At four weeks subjects randomized to the intradermal vaccination (id) arm received a 
regular intramuscular (im) vaccination and subjects randomized to the im arm received 
a reduced dose id vaccination. Antibodies were measured at week 0, 4, 8 and 26 (for a 
subgroup) as presented in Figure 2. In the original publication only the week 4 data are 
represented graphically for reasons of clarity.
The HIV-groups were the only groups that met the predefined size from the power calcula-
tions (90% power to detect a 50% difference in post vaccination GMT in the id versus the 
im group); the other study groups are used as reference groups.
Revaccination at week 4 did not give a true booster response. Titers did increase in all 
study groups (except for the rituximab treated patients), but the effect on the protection 
rate was modest or even absent.
Anti-influenza titers remained stable six months after repeated vaccination in healthy 
controls but not in HIV-infected individuals. This information is relevant in case of ‘late’ 
influenza epidemics (as occurred in The Netherlands 2006 and 2007) and in case of cross-
equator travel, in which cases HIV-infected individuals might be unprotected. Protection 
rates, 6 months after repeated vaccination, were as low as 67, 48 and 29% for influenza 
A/H3N2, A/H1N1 and B, respectively (vs. 100, 71 and 86% in healthy controls; pooled 
data from im and id vaccination). Protection might even be more short lived in subjects 




















































































Figure 2. Geometric mean titers (95% confidence interval) against influenza A/H3N2, A/H1N1 and 
















































































the induction of cross-reactive 
antibodies after influenza vaccination 
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Background. The composition of influenza vaccines is updated annually to match circu-
lating epidemic strains. However, influenza vaccination induces antibodies that cross-react 
with antigenic drift variants to a certain extent. We analyzed the cross-reactivity of serum 
antibody responses after influenza vaccination of human immunodeficiency virus (HIV)-
infected patients and healthy controls.
Methods. Sera of 38 HIV-infected patients and 18 healthy controls who were vaccinated 
with the 2005/2006 trivalent influenza vaccine were tested for the presence of antibodies 
against the homologous influenza A/H3N2 vaccine strain and vaccine strains used in 
subsequent years (2005-2009). Serum antibody titers were determined using the hemag-
glutination inhibition (HI) assay. Geometric mean titers (GMTs) are reported as primary 
outcome.
Results. Antibodies elicited by influenza vaccination cross-react with drift variants. This 
phenomonen is, as expected, dependent on their antigenic distance. The level of cross-
reactivity of anti-influenza antibodies is comparable in HIV-infected individuals and 
healthy controls.
Conclusions. HIV-infected individuals, like healthy controls, are likely to benefit from 
the cross-reactivity of influenza virus specific antibodies elicited by influenza vaccination 
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backGround
Influenza viruses are a major cause of annual outbreaks of respiratory disease. [1-2] These 
viruses display considerable antigenic drift in particular in the hemagglutinin, which is 
driven by antibodies induced by previous infections or vaccination in the general popula-
tion. [3-5] Consequently, new variants emerge that escape recognition by virus neutral-
izing antibodies. The emergence of antigenically distinct influenza A/H3N2, A/H1N1 
and B viruses necessitates the update of the vaccine composition almost annually. [6-9] 
Annual influenza vaccination is recommended for persons at risk for complications of 
infection, including immunocompromised patients. [10]
The extent of cross-reactivity of vaccination-induced antibodies with antigenic drift 
variants depends on several factors most notably the antigenic distance between the vac-
cine strains and the respective epidemic variant strains. [11-13] Specific anti-influenza 
antibody producing memory B-cells can be found in the blood, decades after exposure to 
a specific strain. [14] Protection against distinct influenza strains can occur after natural 
influenza infection; the induction of cross-reactive antibodies may also afford some level 
of protection against deviant influenza virus strains. [15-18] For example, the induction of 
antibodies against the neuraminidase of an influenza A/H1N1 virus even afforded protec-
tion against infection with an A/H5N1 influenza virus in mice. [19]
The high attack rate of the 2009 influenza A/H1N1 virus is facilitated by the scarce pres-
cence of (cross-reactive) antibodies against this strain in the general population. [20-21] 
Cross-reactive antibodies against this new influenza virus have been found in a proportion 
of elderly subjects, most notably those born in the first decades of the twentieth century, 
probably as a result of infection with the antigenically similar 1918 pandemic influenza 
A/H1N1 strain, more than 9 decades before, or the descendant virusses of this strain. 
[22-24] These antibodies provide some clinical protection against the 2009 influenza A/
H1N1. [25] Strategies to profit from the cross-reactivity of anti-influenza antibodies are 
being developed. [26-30]
It has been shown that in the elderly (≥ 75 years of age) the antibody response induced 
by vaccination was less cross-reactive than that of younger subjects, which is thought to be 
caused by immune senescence. [31] This could make this age group more susceptible to 
infection with epidemic influenza virus strains that do not completely match the vaccine 
strains. If this reduced cross-reactivity is indeed caused by immune senescence, we would 
expect to find this phenomenon in HIV-infected individuals as well. Chronic HIV-1 
infection causes immune activation and a generalized inflammatory state, characterized by 
high numbers of activated CD8+ lymphocytes. This T-cell activation causes an accelerated 
immune senescence in HIV-1. [32-34]
To assess the cross-reactivity of vaccine-induced antibody responses of HIV-1 infected 









































controls subjects vaccinated with a 2005/2006 influenza vaccine was tested with influenza 
viruses that circulated in subsequent years.
metHods
Trial design and subjects
The HIV-1 infected patients (HIV group) and control group (HC group) included in 
the current study are a selected subset of subjects from a previous study. [35] Subjects 
with a prevaccination titer <40 and a post vaccination titer ≥40 to influenza A/H3N2 
were included in this sub study. To exclude an influence of pre-existing anti-influenza 
antibodies, subjects with higher prevaccination titers were excluded. The exclusion of non-
responders (a postvaccination titer <40) follows from the fact that the cross-reactivity of 
anti-influenza antibodies could only be determined in subjects with a measurable antibody 
titer. The study protocol was approved by the appropriate institutional ethics committees 
(LUMC, local CME number P05.115; ISRCTN15762138) and conducted in accordance 
with de Declaration of Helsinki. All participants provided a written informed consent.
Vaccine and vaccination
All study subjects were vaccinated in the fall and winter of 2005 with a commercially 
available trivalent subunit influenza vaccine (Influvac™ 2005/2006, Solvay Pharmaceu-
ticals B.V., Weesp, The Netherlands) at day 0. The vaccine contained 15 μg of hemag-
glutinin of each of the following strains: A/California/7/04 (H3N2)-like strain (vaccine 
strain NYMC X-157) further referred to as A/H3N2/California or homologous X-157 
strain; A/New Caledonia/20/99 (H1N1)-like strain (vaccine strain IVR-116) and B/
Shanghai/361/02-like strain (B/Jiangsu/10/03).
Vaccines were stored at 6°C and administered at room temperature and given either 
intramuscular (0.5 mL) according to the package insert or intradermal (0.1 mL) as de-
scribed before. [35]
Antibody assays and statistics
Serum samples were collected at day 28 and were stored at –80°C until use. The hemag-
glutination inhibition (HI) test was performed in duplicate according to standard methods 
with turkey erythrocytes and four hemagglutinating units of virus to measure antibodies 
against each of hemaglutinins as described before. [35] We tested antibodies against influ-
enza A/H3N2 viruses since these subtypes displayed the highest degree of antigenic drift. 
The A/H3N2 strains used in the HI assay were X-157 (the A/California/7/04-like vaccine 
strain for the 2005/06 season: the homologous vaccine strain), and the heterologous 








































Cross-reactive antibodies after influenza vaccination 81
2007/08 seasons) and X-175c (the A/Brisbane/10/07-like vaccine strain for the 2008/09 
and 2009/10 seasons). The antigenic distance between X-157 and X-175c is larger than the 
antigenic distance between X-157 and X-161b. Ferret sera raised against the test antigens 
were used as positive controls against all antigens used in this analysis. All sera were tested 
simultaneously, which included retesting all sera against the homologous vaccine strain. 
For statistical analysis a titer of 5 was arbitrarily assigned to sera with a titer <10. Titers 
were transformed to a logarithmic scale and geometric mean titers (GMTs) were used for 
further calculations. Crude GMTs are reported for all antigens tested.
The results were analyzed by multivariate logistic regression (ANOVA) analysis, using 
natural logarithms of HI titers. A p-value <0.05 was considered to indicate a statisti-




Baseline characteristics of the study subjects are summarized in Table 1. The route of vac-
cination, either intramuscular (im) or intradermal (id), did not influence post-vaccination 
titers in the original, or in the present study. [35] Therefore, data obtained from im and id 
vaccinated subjects were pooled.
table 1. Baseline characteristics of subjects.
characteristics HC HIV p-value
n 18 38










0 61 <0.0001 †






HAART,% - 71 -
† χ-square test (2-sided); ‡one-way ANOVA










































HI titers against the homologous vaccine strain, X-157, were tested in 2006 (for the 
original study) and again for the present study. There was a good reproducibility of the 
original data with a correlation coefficient of 0.90 (p<0.001, Spearman’s rho).
Figure 1 shows GMTs against the homologous and heterologous strains in the two 
study groups. As reported earlier, the (quantitative) antibody response upon influenza 
vaccination is impaired in HIV-infected individuals compared with healthy controls. [35] 


















Figure 1. Geometric mean titers (GMT) against homologous and heterologous (influenza A/H3N2) 
vaccine antigens for the two study groups.
Whiskers indicate 95% confidence interval; dashed line indicates protection threshold (40).
HC: healthy control group; HIV: human immunodeficiency virus group
Figure 2 shows a scatter plot of the (natural logarithm of the) homologous titer X-157 
on the x-axis versus the (natural logarithm of the) heterologous titers X-161b (panel A) 
and the more distant X-175c (panel B) on the Y-axis. The regression lines plotted in panel 
A do not differ significantly between the two study groups. In panel B there is a statisti-
cal significant difference between the two regression lines, indicating that the absolute 
decrease in cross-reactive HI titers was stronger in the healthy control group as compared 
with the HIV group (ANOVA p<0.005). The proportional decrease of the antibody titers 
to X-175c compared to the homologous titer to the X-157 strain was 35% (SD=16) and 
34% (SD=20) in healthy controls and HIV-infected individuals respectively, which is not 








































Cross-reactive antibodies after influenza vaccination 83
In a multivariate regression analysis we did not find an effect of age, gender, vaccination 
route, (nadir) CD4 T-cell count or previous vaccination on the forming of cross-reactive 
antibodies.
In the present study, only previously unvaccinated healthy controls were included, 
because most healthy controls who were vaccinated the year before fulfilled the exclu-
sion criterion of a prevaccination HI titer ≥40. Within the HIV-group, titers a year after 
(previous) vaccination were lower allowing for inclusion of both previously unvaccinated 
and vaccinated patients. Within the subset (61%) of previously vaccinated HIV-infected 
individuals, we found slightly higher pre- and postvaccination titers. The exclusion of 
previously vaccinated individuals did not significantly influence our findings.





























































Figure 2. Scatterplot of (natural logarithm of ) homologous titers against (natural logarithm of ) the two 
heterologous titers (panel A and B) for the two study groups, including regression lines.
Black line: HC; grey line: HIV
HC: healthy control group; HIV: human immunodeficiency virus group










































In the present study we show that the cross-reactive properties of the virus specific anti-
body response of HIV-infected patients, with a median CD4 count of 444 cells / micro-
liter, upon influenza vaccination, are comparable to that of healthy control subjects. This 
preserved qualitative response contrasts with the impaired quantitative antibody response 
in these patients compared with healthy controls, as was reported in an earlier study. [35] 
The present study was done with a subgroup of the study participants (responders) from 
that study.
Although the composition of the influenza vaccine is updated yearly, based on antigenic 
and epidemiological data of circulating epidemic strains, sometimes the vaccine strains do 
not match the epidemic strains completely. [36] Still, antibodies elicited by vaccination 
do cross-react with these antigenic drift variants and may afford some degree of protec-
tion against infection and are therefore a clinically relevant phenomenon. The reason 
to evaluate the cross-reactive properties of postvaccination antibodies in HIV-infected 
individuals were findings in healthy subjects older than 75 years, reported earlier. [31] In 
the elderly the quantitative antibody response upon influenza vaccination is also impaired. 
[37] Moreover, the induction of antibodies that can cross-react with newly emerging 
antigenic variants was reduced in subjects >75 years of age. [31] This would render this 
age group more at risk of morbidity and mortality due to influenza, when novel antigenic 
variants emerge that do not match the vaccine strain. The impaired quantitative antibody 
response of older individuals is most likely caused by immune senescence resulting in 
impaired virus specific T- and B-cell responses. [38-39] Accelerated immune senescence is 
also one of the mechanisms behind the impaired immune response found in HIV-infected 
individuals. [32-34] At present it is unclear why especially the cross-reactive antibody 
response (a qualitative aspect of the immune response) is affected in the elderly (>75 years 
of age) but not in HIV-infected individuals. It might well be that the immunological 
damage in persons aged over 75 years is far greater than in our study population of HIV-
infected individuals. High age is associated with low numbers of naïve B- and T-cells, 
most notably resulting in poor responses upon neo-antigens. Concurrently there are high 
numbers of activated T- and B-cells, creating a pro-inflammatory environment in high 
age. The combination of scarce naïve cells and pre-existing B- and T-cell clones to older 
influenza antigens, might skew the antibody response towards older antigenically related 
strains, a phenomenon known as original antigenic sin. [40] It was demonstrated recently 
that antibodies directed to historic A/H1N1 viruses, cross reacted with the 2009 influenza 
A/H1N1. These antibodies were detected in a substantial proportion of subjects born in 








































Cross-reactive antibodies after influenza vaccination 85
In the present study, the cross-reactivity of the antibodies formed upon vaccination was 
not correlated with the (nadir) CD4 cell count, gender or age. Of note, most patients 
were effectively treated with antiretroviral treatment and severely immunocompromised 
patients, with a CD4 count of less than 200 cells / microliter, were almost absent in 
the present study. We cannot exclude that severely immunocompromised HIV-infected 
individuals do show decreased cross-reactivity.
None of the study participants was older than 75 years. Other studies did not report 
an effect of older age on cross-reactivity either. However these studies, like our own study, 
included less old subjects in their analysis. [41-42]
Sixty one percent of HIV-infected individuals was also vaccinated in the year before the 
study vaccine was administered (2005/2006), as recommended by guidelines, that advice 
annual influenza vaccination. In 2004/2005 the influenza A/Fujian/411/02-like strain 
was used, which is different from the vaccine strain tested in the present study. The fact 
that we reported higher prevaccination titers in subjects who were previously vaccinated 
already signifies the cross-reactive potential of antibodies formed upon influenza vaccina-
tion. [35] Because we aimed to study the cross-reactivity of newly formed antibodies 
upon vaccination, we included only subjects with a prevaccination titer <40 in the present 
study. Within this selected population for the present study, we found no effect of previous 
vaccination on study outcomes.
In conclusion, virus specific antibodies induced after influenza vaccination of HIV-infected 
individuals, effectively treated with antiviral drugs, do not have impaired cross-reactive 
properties compared with those induced in immunocompetent individuals. This may 
be of clinical relevance for HIV-infected individuals, when the epidemic strain does not 
completely match the vaccine strain.
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Design. Rabies vaccine was used as a T-cell-dependent neo-antigen to investigate several 
aspects of the primary and booster immune response in vivo in HIV-infected individuals 
receiving antiretroviral treatment.
Methods. Subjects received rabies vaccination twice, with a three months interval. Serum 
samples were taken before and 1, 2 and 4 weeks after both vaccinations and 1 and 5 years 
after the primary vaccination. Anti-rabies antibodies (IgG, IgG subclasses, IgA and IgM) 
were determined; antibody avidity was measured after both vaccinations. T-cell subsets 
were characterized by flow cytometry.
Results. Eighteen healthy controls and thirty HIV-infected adults, treated with HAART 
for almost 4 years, with a median CD4+ T-cell count of 537 cells per μL were immunized. 
The post vaccination concentrations of anti-rabies IgG and IgM were significantly lower 
in HIV-infected individuals as compared to controls. Three T-cell-dependent processes, 
a true booster response, a class switch from IgM to IgG and avidity maturation, were 
present in both healthy controls and HIV-infected individuals. Higher age was associated 
with lower post-vaccination anti-rabies IgG and IgM titers. Five years after the primary 
vaccination, 63 percent of the HIV-infected individuals still had antibody titers above the 
protection threshold.
Conclusion. Immune restoration in HIV-infected individuals treated with HAART, re-
sulting in a CD4+ T-cell count greater than 500 cells per μL, is incomplete. However, the 
majority of HIV-infected individuals is capable to mount a long lasting immune response, 
including several pivotal T-cell-dependent processes, upon vaccination with a neo-antigen 
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IntroductIon
Highly active anti-retroviral therapy (HAART) effectively suppresses HIV replication, 
resulting in diminished immune activation and functional immune recovery of both T- 
and B-lymphocytes, reflected in a decline in morbidity and mortality due to opportunistic 
diseases. [1-6] The increase in number of peripheral blood CD4+ T-cells after HAART 
initiation is a composite of an initial redistribution of predominantly memory cells from 
lymph nodes followed by a continuous slow repopulation with naïve T-cells. [7,8] Within 
several months after initiation of HAART partial recovery of the CD4+ T-cell repertoire 
is observed. It has not yet been well established to what extent the quantitative increase 
in CD4+ T-cells is a reflection of reconstitution of the qualitative immune function in 
HIV-infected individuals. [9] Several studies conducted in the HAART era have shown a 
functional but incomplete recovery of T-cell mediated immunity after HAART initiation 
in HIV-infected individuals. [10-13]
Vaccination with a T-cell-dependent neo-antigen like the rabies vaccine is an elegant 
approach to study various aspects of the humoral and cellular immunity in vivo, since 
antibody production, and features of memory responses such as class switch from IgM 
to IgG antibodies, the forming of a booster reaction (a logarithmic titer increase within 
days after re-exposure to the antigen) and avidity maturation (clonal selection of the most 
specific antibodies) all are T-cell-dependent processes. [14]
We studied these responses in chronically HIV-infected individuals, who were on treat-




HIV-1-infected adults from the Infectious Diseases outpatient clinic of the Leiden 
University Medical Center, treated with HAART for at least 6 months, were invited to 
participate in this study. Healthy adults, with no risk factors for HIV, served as controls. 
All participants were naïve to the rabies vaccine. The protocol was approved by the lo-
cal ethics committee (local protocol number P98.220). A written informed consent was 
obtained from all participants.
Vaccine
All subjects received 1.0 mL of a commercially available rabies vaccine (human diploid 
cell vaccine (HDCV), containing inactivated rabies virus (Wistar PM/WI 38-1503-3M 









































(primary vaccination) and week 12 (booster vaccination), administered intramuscular in 
the deltoid region, according to the package insert. [15] The rabies vaccine was chosen 
because it represents a true neo-antigen and the immune response upon this antigen is 
T-cell-dependent. The vaccination schedule used in the present study includes fewer doses 
than routine pre- or post-exposure schedules (consisting of either 3 doses at days 0, 7 and 
21 (28) or 5 doses at days 0, 3, 7, 14 and 28, using 1.0 mL on each occasion). The 0 and 
3 months schedule was preferred in the present study because it represents a more optimal 
timing for priming (a process that takes far more time than 3 or 7 days) and subsequently 
a true booster response.
ELISA for quantification of antibodies against Rabies
Blood samples for serological follow up were taken at 0, 1, 2, 4 weeks after primary and 
booster vaccination, which were 12 weeks apart, and 1 and 5 years after the primary 
vaccination. Sera were stored at -20º C until use; all serum samples from the first 16 weeks 
were tested at once, the sera from the one and five year follow up were tested at a later 
point in time.
Anti-rabies antibodies were quantified by a rabies specific enzyme linked immunoassay 
(ELISA) as described before, using labeled polyclonal antibodies for detection of IgG, IgA 
and IgM and monoclonal antibodies for detection of IgG1 and IgG3. [16]
Although this ELISA does not measure neutralizing antibodies per se, there is a high 
correlation between the antibodies measured by ELISA and neutralizing antibodies and 
WHO, CDC and local agencies endorse the use of ELISA in stead of the more elaborate 
neutralizing antibodies measurements for the assessment of vaccine efficacy. [17,18] Fur-
thermore, our primary end-goal was an immunological comparison between groups, for 
which both tests are equally suitable.
Avidity testing
The avidity of anti-rabies IgG subclasses was measured by a modified elution ELISA 
as described before. [16] The relative avidity index (AI) was defined as the molarity of 
NaSCN at which 50% of the amount of anti-rabies IgG subclasses remained bound to the 
coated rabies antigen.
T-cell subsets
Phenotypic analysis of T-cell subsets was done by flow cytometry (FACSCalibur, Becton, 
Dickinson Biosciences, San Jose, CA, USA). CD4+ and CD8+ lymphocytes were char-
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Analysis
Antibody titers were log transformed for calculations. Seroconversion was defined as a 
post vaccination IgG anti-rabies antibody titer equal to or greater than 0.5 IU/mL as 
issued by the World Health Organization (WHO). [19] The protection rate was defined 
as the percentage within a group with a titer greater than or equal to 0.5 IU/mL.
To quantify the booster response, the anti-rabies IgG titer fold increase in the first week 
following both vaccinations was calculated. A class switch, the relative decrease of IgM 
antibody in favor of an increase of IgG production after booster vaccination, was arbitrarily 
defined as a decrease of anti-rabies IgM after booster vaccination as compared to the IgM 
response after the primary vaccination. Avidity maturation was calculated as the fold in-
crease in avidity measured at week 16 versus week 4. A linear regression model was used to 
identify clinical and immunological parameters correlated with these vaccination outcomes.
All analyses were carried out using SPSS software (version 15.0). A two-tailed P value 
of less than 0.05 was considered to be statistically significant. Separate time points were 
tested as independent variables.
results
Study population
Thirty HIV-infected individuals and 18 healthy controls were enrolled in this study. Im-
munological and clinical parameters of the study subjects are summarized in Table 1; 





Age, mean, years (range) 31 (19-49) 45 (21-71)
Gender,% male 50 97
CDC stage A / B / C (%) - 43 / 23 / 33
Duration HAART treatment, mean (range), years - 3.4 (0.7-5.9)
CD4+ T-cell count (median (IQR), cells/μl)
- nadir
- t=0
CD4+ T-cell phenotype (%)






32 / 48 / 20
HIV-1 viral load, median (range), 10log c/mL
- pretreatment
- t=0




















































Figure 1 summarizes CD4+ T-cell counts and HIV-1 RNA viral load over time. At the 
time of primary vaccination the median duration of HAART was 41 months (range 8-71 
months). No serious adverse events were reported upon vaccination. One healthy subject 
showed an allergic reaction (urticariae, clinical diagnosis) ten days after booster vaccina-
tion, which subsided without intervention.
All 30 HIV-infected individuals could be included in the 5 year follow up; this last 
serum sample was drawn after a mean of 268 (range 250-293) weeks, at which time point 
these patients were on HIV treatment for almost 9 years. HIV-1 RNA concentrations were 
measured before and one week after both vaccinations and were not influenced by the vac-
cination. Only a minority of patients had a detectable HIV-RNA load at any time-point 
during the five years follow-up (respectively 5, 3 and 5 patients at t=0, 12 and 268 weeks). 
Of the five patients with a detectable viral load 5 years after t=0, three patients had ‘blips’ 
with a transient detectable viral load <150 c/mL and one patient had stopped HIV therapy 
with a CD4+ T-cell number persisting around 500 cells per microliter. No CD4+ T-cell 
counts were determined in healthy controls. Eleven of the 18 healthy controls were either 
lost to follow up or were excluded from the 5 year follow up because they had received a 
booster vaccination after 1 year as part of a different study protocol. [16]
Antibody titers
The prevaccination concentrations of IgG (Figure 2), both IgG1 and IgG3, but not IgM 
(data not shown) anti-rabies antibody titers were significantly higher in patients as com-
pared to healthy controls (P < 0.01). Post vaccination antibody titers (at all time points) 
were independent of the prevaccination titer.
The post vaccination concentrations of IgG, IgM and IgA anti-rabies were significantly 
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Figure 1. Time schedule of trial, with CD4+ T-cell count (cells/µL, line represents median, box represents 
25 and 75 percentiles, whiskers represent range) and HIV-RNA (copies/mL, dashed line and diamonds 
represent median, whiskers (only at t=-41 (pre treatment) represent range). Pretreatment values are 
projected at t=-41 months (mean number of months on antiretroviral therapy (ART) at t=0). Small arrows 
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2; IgM and IgA data not shown), at all time points from week 2 to 4 and week 12 to 16, 
except for IgM at week 14 and 16, in an univariate analysis.
Both a lower number of naïve CD4+ T-cells and higher age were associated with sig-
nificantly lower (anti-rabies IgG and IgM) titers 2-4 weeks after primary vaccination, but 
not after booster vaccination in an univariate analysis. Age and the number of naïve CD4+ 
T-cells were inversely correlated (Spearman’s rho coefficient -0.55, p=0.002).
In a multivariate regression model, controlling for sex, age and study group (healthy 
control vs. HIV), only higher age (and not HIV-infection) was associated with lower 
vaccination titers upon primary vaccination (week 2, 4, and 12). For the booster response 
(time points 13, 14 and 16 weeks) only HIV-infection was associated with lower anti-
rabies IgG titers.
Patients with a detectable viral load at t=0 (n=5) yielded two- to threefold lower anti-
rabies (IgG and IgM) concentrations, at all time points from week 2 to 16, as compared 
to patients with an undetectable viral load. Three out of these five patients only had a low 
level of viral replication with HIV RNA <250 copies/mL. The effect of detectable HIV-
RNA on anti-rabies IgG titers was independent of the CD4+ T-cell count, but statistically 
significant only at one time point (t=14 weeks) for anti-rabies IgG. The Center for Disease 
Control classification or the duration of HAART were not correlated with vaccination 
outcomes.
Individual response patterns varied greatly among the 30 HIV-infected individuals 
(Figure 3). Analysis of IgG subclass antibodies to rabies showed that the IgG response 
mainly consisted of IgG1 and IgG3. [16] Seroconversion, defined by the WHO as a post 
vaccination titer greater than or equal to 0.5 IU/ml, a level considered to be protective 
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Figure 2. Total anti-rabies IgG titers (IU/mL) in time. Error bars indicate 95% confidence interval and small 
arrows on x-axis indicate timing of primary and booster vaccination.
* denotes p<0.05 in multivariate regression model, after correction for age.









































Antibody levels tested 5 years after the primary vaccination were still above this protec-



























Figure 3. Age versus actual anti-rabies IgG titers (IU/mL) for all individual subjects (open circles: healthy 
controls; closed triangles: HIV-infected individuals) at week 4 and 16. Pearson’s correlation coefficient (r) 
and p value calculated with log transformed titers.
Week 4: HC r= -0.484 (p<0.05), HIV r= -0.573 (p<0.01);
week 16: HC r= -0.356 (ns), HIV r= -0.205 (ns).
HC: healthy controls; HIV: HIV-infected individuals; ns: not significant.


























Figure 4. Percentage of subjects with a protective titer (anti-rabies IgG≥ 0.5 IU/mL) at the different time 
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T-cell-dependent processes
Booster response
IgG anti-rabies titers increased 24 fold (range 7-64) in healthy controls and 11 fold 
(range 1-30) in HIV-infected individuals (ANOVA, p=0.001) within the first week after 
booster vaccination. Six out of 30 HIV-infected individuals (and nil out of 18 healthy 
controls) had a less than 5 fold titer increase. The magnitude of this booster response in 
HIV-infected individuals was not related to any of the other clinical or immunological 
parameters, such as CD4+ T-cell count, CD4+ T-cell nadir, viral load or age.
Class switch
A decrease of the IgM response after revaccination as compared to the IgM response 
after primary vaccination was seen in 83% of healthy controls and 60% of HIV-infected 
individuals (Pearson’s Chi-Square test, p=0.091). The probability of such a decreased 
IgM response upon booster vaccination in the HIV-infected individuals was significantly 
correlated with the total number of CD4+ T-cells at the time of (primary) vaccination 
(Spearman’s rho p=0.04); the median number of CD4+ T-cells in the group that did not 
show a class switch was 421 cells per microliter (range 86-803) as compared to 573 (range 
222-1693) in the group that did show a class switch.
Avidity maturation
The avidity of IgG1 and IgG3 anti-rabies antibodies in HIV-infected individuals showed 
a significant increase at week 16 as compared to week 4, which was stronger in healthy 
controls than in HIV-infected individuals. Regarding IgG1 the mean fold increase (stan-
dard deviation) was 1.36 (0.17) for healthy controls and 1.30 (0.12) for HIV-infected 
individuals (ns); for IgG3 the mean fold increase (standard deviation) was 1.51 (0.28) 
for healthy controls and 1.34 (0.17) for HIV-infected individuals (p<0.05 ANOVA). The 
increase of avidity was independent of the total number of CD4+ T-cells.
dIscussIon
HIV-infected individuals, who were treated with HAART for more than three years result-
ing in a normalized CD4+ T-cell number, yielded significantly lower post vaccination 
titers as compared to healthy controls after booster rabies vaccination. Still, even after 
only two vaccinations the protection threshold, as defined by the WHO, was met by all 
subjects. Five years after the vaccinations almost two thirds of the HIV-infected individu-









































Three individual T-cell-dependent processes, which add up to an overall functional 
quantitative and qualitative immune response, all appeared to function at an adequate 
level in these HIV-infected individuals. First, a rapid booster (memory) response could 
be identified in most HIV-infected individuals and all healthy controls. Second, an 
immunoglobulin class switch from predominantly IgM to IgG antibodies was equally 
present in healthy controls and HIV-infected individuals. Third, a significant increase in 
antibody avidity after repeated vaccination, a process of clonal selection of the most spe-
cific antibody producing cells, was present in both HIV-infected individuals and healthy 
controls. Although all these processes are considered to be dependent on the number 
(and functioning) of CD4+ T-cells, only the class switch showed a statistically significant 
correlation with the number of CD4+ T-cells at the time of vaccination in the present 
study. Overall, the magnitude of the booster response was less in HIV-infected patients as 
compared to healthy controls but independent of the CD4+ T-cell count.
Several studies have shown that the immunological impairment caused by HIV is only 
partially reversed by antiretroviral treatment, even with a full recovery of the CD4+ T-cell 
count. [10-13, 20] The severity of this immunological ‘scar’ has been linked to numerous 
factors. The depth of the pre-treatment CD4+ T-cell nadir, thymic function and/or age, 
genetic factors, baseline viral load, the presence of HIV-RNA and the number of CD28 
expressing CD4+ (central memory) T-cells, an essential co-factor for T-cell activation by 
stimuli such as a vaccine antigen, have all been implicated among others. [21-32] Cur-
rently, several studies support initiating HAART at higher CD4+ T-cell counts to prevent 
HIV-related morbidity and mortality, associated with ongoing viral replication and loss of 
immunological function. [33-38]
The present study is unique in that it contains a long-term follow up of patients with a 
quite severe pre-HAART immunodeficiency: 63% of the patients had a nadir CD4+ T-cell 
count of less than 200 and one third even less than 100 cells per microliter. The fact that 
a proper response upon a T-cell-dependent neo-antigen could be mounted despite a low 
CD4+ T-cell nadir underscores the complex but resilient nature of the immune system.
Vaccination studies in HIV-infected patients, like our own study, typically have a relatively 
small sample size and a limited immunological evaluation of the subjects, impairing the 
power to detect factors associated with a poor vaccination outcome. (Partial) immune 
recovery in the HAART era has been described for many vaccines including the influ-
enza vaccine. [39-46] The most extensively studied vaccine in HIV-infected individuals 
is probably the hepatitis B virus (HBV) vaccine. HIV-infected individuals show a poor 
response upon the standard HBV vaccination (protection rates of 18-56%, even in the 
HAART era, contrasting with >90% in healthy controls). Clinical factors such as male 
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such as a low number of CD4+ T-cells or CD4+ memory cells and a high number of 
activated (CD38/HLA-DR positive) CD8+ cells have been associated with a worse HBV 
vaccination outcome. [29, 44-46] Even though the number of patients with a detectable 
viral load was very low in the present study and the majority of these patients only showed 
low level viremia, the presence of HIV-RNA in the plasma was associated with lower post 
vaccination titers upon rabies vaccination, possibly through immune activation.
Only a few studies report on rabies vaccination in HIV-infected patients: a poor antibody 
response on both pre- and post-exposure immunization schedules has been described in 
HIV-infected individuals with low CD4+ T-cell counts. [47-51] Guidelines consider rabies 
vaccination safe for this patient group and advise to measure the effect of the immuniza-
tion, which consists of 3 vaccinations administered within four weeks. [52] The necessity 
of booster vaccinations for long term protection, especially for immunocompromised 
patients, is underscored by the present study.
The relatively high prevaccination concentrations of IgG anti-rabies in the HIV-infected 
individuals might be caused by cross-reactivity of antibodies against HIV gp120 with 
a rabies glycoprotein, which share a structurally and functionally related site. [53] The 
height of the prevaccination titers in HIV-infected patients in the present study did not 
affect the antibody responses upon subsequent primary and booster rabies vaccination.
In conclusion, the antibody response upon vaccination with a neo-antigen such as the rabies 
vaccine is impaired in HAART treated HIV-infected patients despite quantitative CD4+ 
T-cell recovery. However, functionally and clinically important aspects of the adaptive 
immunity such as the booster response, class switch and avidity maturation upon booster 
vaccination do seem to be operational and protective anti-rabies titers were induced in 
all subjects after only two vaccinations. These findings have important consequences for 
other vaccination strategies and vaccines, including HIV vaccines.
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Vaccination has been shown to be one of the most powerful tools to decrease morbidity 
and mortality caused by numerous infectious diseases. The risk of (complications of ) 
some vaccine preventable diseases is higher in HIV-infected individuals, underscoring 
the importance of vaccination in these patients. However, the response upon vaccination 
is generally impaired and shorter lasting in HIV-infected individuals, especially in those 
with low CD4 T-lymphocyte counts and detectable HIV-RNA, as compared to healthy 
controls. Even in patients successfully treated with anti-retroviral treatment, an impaired 
immune response may persist despite normalization of the CD4-cell count.
Caution with live attenuated vaccines is warranted in HIV-infected individuals with 
low CD4 T-lymphocyte counts. Decisions about administering a live attenuated vaccine 
should be made after weighing the risks and benefits on an individual basis. In this article 
we review the immunology of vaccination in HIV-infected individuals, as well as the most 
relevant caveats of vaccination in this patient group. The currently available information 
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IntroductIon
Preventing or mitigating disease by vaccination is one of the most (cost-)effective interven-
tions in medicine. [1] Routine vaccination programs for adults, that typically include 
booster vaccinations every decade against diphtheria, tetanus, pertusis and polio, also 
apply to HIV-infected adults. [2] In addition, influenza, pneumococcal, hepatitis A virus 
and hepatitis B virus vaccines, are indicated in (most) HIV-infected adults. [3-5] The 
effectiveness and safety of vaccines that prevent travel associated infections might be lower 
in HIV-infected individuals as compared to healthy individuals. [6]
Numerous clinical and immunological factors have been correlated with an impaired 
immune response upon vaccination; most notably a low CD4 count and a detectable 
HIV-RNA at the time of vaccination. [7-13] Most clinical and immunological vaccination 
studies in HIV-infected individuals, including our own studies, are relatively small in 
sample size and rely on surrogate parameters, such as antibody titers, as primary outcome.
This review summarizes the general principles of vaccination of HIV-infected adults, 
with the currently registered vaccines (thus excluding e.g. HIV vaccines and other vaccines 
in development) and refers to relevant practical guidelines.
General consIderatIons
The immunology of vaccination and HIV
Although readily quantified by measuring the number of CD4+ T-lymphocytes, the im-
munodeficiency that defines HIV/AIDS is more complex than just a lack of periferal 
T-cells. [14-15] The HIV induced depletion of CD4+ T-lymphocytes from its natural 
reservoirs and the subsequent translocation of antigens from the gut sets of a complex 
disruption of humoral and cellular immunity and lymphoid tissues. [16-19] Immune 
activation and inflammation are important components of this process, that becomes 
visible in lymph nodes. Lymph nodes in chronic HIV-infection are filled with activated 
T-and B-cells, in part reactive against HIV, disrupting both architecture and function of 
the lymphoid tissue. [20-21] The actual immune response upon vaccination takes place 
in these hyperplastic lymph nodes, after the vaccine antigens have been transported by 
antigen presenting cells from the vaccination site to the draining lymph node. In these 
lymph nodes follicular dendritic cells capture and retain the antigen, presenting it to 
antigen-specific B-cells that subsequently undergo clonal expansion, forming germinal 
centers in which HIV is also abundantly present. With the help of follicular B-helper 
T-cells (TFH-cells) memory B-cells are formed, that facilitate a booster response upon 
a second encounter with the identical antigen. [22] Although relatively little is known 









































responses upon both T-cell-independent and T-cell-dependent antigens are impaired. In 
general, patients with a CD4 cell count less than 200 cells / μl are considered severely im-
munocompromised, those with CD4 cell counts in between 200 and 500 cells moderately 
and those with a CD4 cell count > 500 are considered to have a near normal immunity.
Antiretroviral treatment has brought a tremendous shift in the morbidity of HIV-
infected individuals; opportunistic diseases have become exceedingly rare in those who 
receive medical care, even if the CD4 cell number does not fully recover. [23-25] This 
is a clear sign that HIV-treatment is followed by functional immune recovery. There are 
however many studies that show that this immune recovery is not complete and that an 
‘immunological scar’ remains, even after many years of successful HIV-treatment. [26-
28] As illustrated in Figure 1, the typical response upon vaccination in HIV-infected 
individuals is impaired both in magnitude and longevity as compared to healthy controls. 
[29] Clinical failure of vaccination has been described. [30-31] Whether or not an earlier 
initiation of ART, at higher CD4-cell counts, might prevent immunological damage and 
thus aid to limit this scar is currently unknown. [32-34] The clinical importance of this 
immunologic scar might be limited. We found that many aspects of the T-cell-dependent 
immune responses upon a T-cell-dependent neo-antigen were functional in a group of 
HIV-infected individuals who had reached extremely low CD4 nadir counts in the pre-
ART era but who subsequently reconstituted after the initiation of HAART. A booster 
response, class switch and affinity maturation were observed, as proof of the functionality 
of the newly formed CD4+ T-lymphocytes in these patients. [35]
Detectable HIV-RNA is a factor, independent of the CD4 cell count, that has been 
associated with impaired responses upon vaccination in several studies. [12,13] The 
underlying mechanism might be ongoing immune activation and inflammation or HIV-
induced apoptosis of activated T-cells involved in the immune response upon the vaccine 
antigen. [36]
Almost all vaccination studies in HIV-infected individuals revert to surrogate pa-
rameters such as antibody levels or specific T-cell responses to measure the quantitative 
response upon vaccination, since clinical endpoints (such as pneumonia in pneumococcal 
vaccine studies) are infrequent and only large field studies can determine an effect on mor-
bidity and mortality. [37] Antibody levels correlate well with clinical protection (at least 
in healthy subjects). The antibody level that is considered protective is usually identical 
in healthy controls and immunocompromised patients such as HIV-infected individuals.
Optimizing the efficacy of vaccination
Vaccination should preferably be postponed in patients with a severe immunodeficiency (a 
CD4 count of less than 200 cells per μl) if immune reconstitution and viral suppression is 
to be expected within a reasonable period of time. Patients treated with steroids for PCP 

















































































Figure 1. Twenty six weeks follow up of geometric mean titers (GMTs) of anti-influenza A/H3N2, A/H1N1 
and influenza B antibodies upon influenza vaccination at week 0 and 4 for HIV-infected individuals (HIV, 
n=80, median CD4 T-cell count 463 cells/µl (IQR 293-415); 83% treated with ART, 74% undetectable (<40 
c/ml) HIV-RNA) and healthy controls (HC, n=41). Represented are the pooled data from subjects who 
received intradermal and intramuscular vaccinations (seasonal vaccine 2005-2006). [29]









































vaccines or travel related vaccines should be administered when indicated, with some 
restrictions for live attenuated micro-organism and knowing that the immune response 
might be sub optimal. Determining post vaccination titers (e.g. after HAV and HBV vac-
cination) in HIV-infected adults identifies those who are unprotected upon vaccination 
and might subsequently benefit from alternative measures to protect them from disease.
Since the antibody response upon vaccination can be short lived, earlier re-vaccination 
might be necessary in HIV-infected individuals as compared to healthy controls.
Many strategies have been explored to optimize the response upon vaccination in 
immunocompromised patients. These strategies include higher vaccine doses, increased 
vaccination frequency, different formulations, addition of adjuvants, or different routes 
of administration (e.g. mucosal or intradermal). [29, 38-40] None of these strategies has 
been proven powerful enough to replace the routine practice.
Adverse reactions
Local and non serious adverse reactions, such as pain, myalgia and fever, do occur after 
vaccination in a frequency comparable to that in healthy controls. Local skin reactions 
upon intradermal vaccination occur less frequent in immunocompromised patients than 
in healthy controls. [29] It is unknown if severe but rare side effects, such as Guillain-
Barré Syndrome after influenza vaccination, occur disproportionably more often in HIV-
infected individuals, who are already prone for this condition. [41-42]
Some level of immune activation is necessary to mount an immune response upon 
vaccination. [22] This immune activation is usually mild, but might be accompanied by a 
transient rise of HIV-RNA, which most likely represents a transient increase of the residual 
viremia and not an overall increase of viable virus. [43-44] The impact of vaccination on 
the natural course of HIV-infection is likely to be marginal and not clinically relevant.
Live vaccines
As a general rule, live attenuated vaccines are contra-indicated in patients with an im-
munodeficiency, since the vaccine strain could be pathogenic and cause a variant of the 
disease it should prevent, if the immunity fails to neutralize the vaccine strain. Reports of 
disease caused by attenuated vaccine strains are rare, with the exception of lymphadenitis 
and other complications caused by the M. tuberculosis-vaccine strain Mycobacterium bovis 
BCG. [45-50]
Three vaccines (Yellow Fever (YF); measles, mumbs and rubella (MMR) and varicella 
zoster virus (VZV)) are generally considered safe if the CD4-positive lymphocyte count 
is higher than 200 cells/μL. [3-4] A recent study showed that YF vaccination was safe 
and effective in HIV-infected adults with a median CD4-count higher than 500 cells/μL. 
Although this study included a few patients with a CD4-positive lymphocyte count of less 
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the rare but severe complications of YF vaccination. [51] The indication for Yellow fever 
vaccination should carefully be made: for visitors to non-endemic countries a vaccination 
weaver could be preferred, while for persons visiting endemic YF area’s the vaccine risks 
might be outweighed by the risks of contracting the disease.
Drug interactions
Vaccines are not dependent on (hepatic) metabolization or renal clearance and pharmaco-
kinetic interactions are not an issue in the vaccination of HIV-infected individuals. There 
are however some (potential) interactions that deserve consideration.
For some flavi-viruses, including West Nile virus and Yellow Fever, a worse outcome 
has been described in patients with a dysfunctional or absent CCR5 receptor. [52-53] 
Therefore, the use of the Yellow Fever vaccine might not be safe in patients treated with 
CCR5 inhibitors, such as maraviroc and vicriviroc, as recently hypothesized. [54-57] The 
use of (pegylated-)interferon in patients co-infected with hepatitis C might prevent the 
necessary replication of a live vaccine virus strain, and thus prohibit an adequate immune 
response. However, data that support these hypotheses are lacking.
GuIdelInes For clInIcal PractIce
Table 1 summarizes vaccine characteristics and efficacy data of commonly used vaccines in 
HIV-infected adults. [3,36,58] Practical guidelines for the immunization of HIV-infected 
adults are widely available online and should be integrated in the complex care of HIV-
infected individuals. [2-6; 59] Adherence to these guidelines often is suboptimal. [60] 
Vaccination status (for e.g. HBV) and indications (for e.g. influenza) should explicitly be 
mentioned in the communication with the primary health care providers and patients.
tHe 2009 InFluenza a/H1n1 monoValent VaccIne
The introduction of an antigenically and genetically new human influenza A/H1N1 virus 
in April 2009 poses many new challenges. [61] This virus is a neo-antigen for the majority 
of the population, although there are clear indications of cross-reactive antibodies found 
in those who were infected with the 1918 influenza A/H1N1 and its daughter viruses. 
Some clinical protection is found in elderly (>60 years of age) who have been in contact 
with related influenza A/H1N1 viruses that circulated until many decades ago. [62-65] 
The T-cell-dependent neo-antigen vaccine was expected to generate a relatively weak and 
short-lived antibody responses, especially in individuals with a compromised T-cell im-









































table 1. Characteristics of vaccines and vaccine response in HIV-infected individuals.


















↑ ↓ Most studies done with children
Hepatitis A 2 (inactivated, 
im)
↑ ↓ Response rates correlate with CD4 count
Hepatitis B 2 (surface anti-
gen, im)
↑ ↓ Response rates correlate with CD4 count
Human papil-
loma virus
2 (virosomal, im) ↑ ‘vaccine efficacy might be less’ but no clinical trials yet
Influenza 
(seasonal)
2 (split or sub-
unit, im)
=/↑ ↓ Response reduced with CD4 count < 200
3 (intranasal) =/↑ = Contraindicated; no prolonged viral shedding; 
seroresponse comparable to placebo in HIV and HCs †
MMR 3 (im) ↑ 
(measles)
=/↓ Durability of response may be reduced
Meningococ-
cus
1 (PS, im) = ↓ Limited data; durability of response may be reduced
2 (conjugated, 
im)
= No published data
Pneumococ-
cus
1 (PS, im) ↑ =/↓ Shorter lasting protection due to lower peak antibody 
titers postvaccination; increased incidence of pneumonia 
in vaccinated adults (but decreased all cause mortalitiy)
2 (conjugated, 
im)
↑ ↓ Limited data; prime (conjugate)-boost (polysaccharide) 
strategies have been explored
Poliomyelitis 2 (inactivated 
(IPV), im)
= =/↓ Secondary (booster) response impaired with CD4 count 
< 300
3 (OPV, oral) = Most studies done with children; contraindicated
Rabies 2 (inactivated, 
im)
= ↓ Shorter lasting protection due to lower peak antibody 
titers postvaccination
Smallpox 3 (vaccinia, 
intradermal)
↑ contraindicated
Tetanus 2 (toxoid, im) = =/↓ tetanus immunogenic (but less than HCs)
Typhoid fever 1 (PS, im) ↑ ↓ Response rates correlate with CD4 count
3 (Ty21a, oral) ↑ Contraindicated





3 (Oka strains, 
im)
↑ = Limited data; may be used with CD4 >200
Yellow fever 3 (17D strain, 
im)
= ↓ May be used with CD4 >200; faster decline of 
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count less than 200 cells/μL. HIV-infected individuals with adequate immune restoration 
upon treatment with antiretroviral therapy responded just as well as healthy controls upon 
primary vaccination with a T-cell-dependent neo-antigen. [35]
Three kinds of (monovalent) vaccines are being produced against influenza A/H1N1 
2009, none of which include antigens that protect against seasonal influenza. [66] The 
unadjuvanted subunit vaccine and the live-attenuated virus vaccine are being produced 
with similar methods as the seasonal influenza vaccines, the latter being contraindicated 
in HIV-infected individuals. To increase the antibody response upon vaccination, an adju-
vanted monovalent vaccine is also being developed. Repeated vaccination ≥ 3 weeks after 
primary vaccination is advised for all three vaccines. Although an interval shorter than 
three months is too short to generate a true booster response, repeated vaccination will 
lead to higher titers as is shown in figure 1 (for the seasonal influenza vaccine). There are 
no data yet about the antibody response upon the 2009 influenza A/H1N1 monovalent 
vaccine in immuncompromised individuals.
HIV-infected individuals aged 25 – 64 years are among the groups indicated for vacci-
nation with the 2009 influenza A/H1N1 monovalent vaccine according to the Centers for 
Disease Control and Prevention (CDC). [66] Reduced dose intradermal (unadjuvanted) 
seasonal influenza vaccination was as immunogenic as full dose intramuscular vaccination 
in HIV-infected adults. [29] This strategy, although not tested with this neo antigen, 
might be helpful in times of vaccine shortages.
conclusIons
Most vaccines can be administered safely and effectively in HIV-infected individuals when 
certain precautions are taken. Complications from live attenuated vaccines, although rare, 
do occur in immunocompromised patients. Often safe alternatives for protection are 




3: live attenuated (generally contra-indicated)
Im: intramuscular; PS: polysaccharide; id: intradermal; HCs: healthy controls
‡ More (↑), equal (=) or less (↓) as compared with healthy controls
‡‡ Better (↑), equal (=) or worse (↓) as compared with healthy controls










































 1. Plotkin SL, Plotkin SA: A Short history of vaccination. In: Vaccines (fith edition). Plotkin 
SA, Orenstein WA, Offit PA (Ed.), Saunders Elsevier Inc., Philadelphia, USA, 1-16 (2008).
 2. Advisory Committee on Immunization Practices. Recommended adult immunization sched-
ule: United States, 2009*. Ann Intern Med. 150(1), 40-44 (2009).
 3. Geretti AM; BHIVA Immunization Writing Committee, Brook G, et al. British HIV Asso-
ciation guidelines for immunization of HIV-infected adults 2008. HIV Med. 9(10), 795-848 
(2008).
 4. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H; Centers for Disease Control 
and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the 
Infectious Diseases Society of America. Guidelines for prevention and treatment of opportu-
nistic infections in HIV-infected adults and adolescents: recommendations from CDC, the 
National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases 
Society of America. MMWR Recomm Rep. 58(RR-4), 1-207 (2009).
 5. Fiore AE, Shay DK, Broder K, et al; Centers for Disease Control and Prevention (CDC); Ad-
visory Committee on Immunization Practices (ACIP). Prevention and control of influenza: 
recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. 
MMWR Recomm Rep. 57(RR-7),1-60 (2008).
 6. Chadwick DR, Geretti AM. Immunization of the HIV infected traveller. AIDS. 21(7), 787-
794 (2007).
 7. Resino S, Rivero L, Ruiz-Mateos E, et al. Immunity in HIV-1-infected adults with a previous 
state of moderate-severe immune-suppression and more than 500 CD4+ T cell after highly 
active antiretroviral therapy. J Clin Immunol. 24, 379-388 (2004).
 8. Lange CG, Lederman MM, Medvik K, et al. Nadir CD4+ T-cell count and numbers of 
CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 
infection. AIDS. 17, 2015-2023 (2003).
 9. Chehimi J, Azzoni L, Farabaugh M, et al. Baseline viral load and immune activation deter-
mine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects 
undergoing antiretroviral treatment. J Immunol. 179, 2642-2650 (2007).
 10. Veiga AP, Casseb J, Duarte AJ. Humoral response to hepatitis B vaccination and its rela-
tionship with T CD45RA+ (naïve) and CD45RO+ (memory) subsets in HIV-1-infected 
subjects. Vaccine. 24, 7124-7128 (2006).
 11. Goicoechea M, Smith DM, Liu L, et al. Determinants of CD4+ T cell recovery during sup-
pressive antiretroviral therapy: association of immune activation, T cell maturation markers, 
and cellular HIV-1 DNA. J Infect Dis. 194, 29-37 (2006).
 12. Overton ET, Nurutdinova D, Sungkanuparph S, Seyfried W, Groger RK, Powderly WG. 
Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat. 
14(3), 189-193 (2007).
 13. Overton ET, Sungkanuparph S, Powderly WG, Seyfried W, Groger RK, Aberg JA. Undetect-
able plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected 
persons. Clin Infect Dis. 41(7), 1045-1048 (2005).
 14. Schacker T. The role of secondary lymphatic tissue in immune deficiency of HIV infection. 








































Vaccination of HIV-infected adults 115
 15. Moir S, Ho J, Malaspina A, et al. Evidence for HIV-associated B cell exhaustion in a dys-
functional memory B cell compartment in HIV-infected viremic individuals. J Exp Med. 
205,1797-1805 (2008).
 16. Levesque MC, Moody MA, Hwang KK, et al. Polyclonal B cell differentiation and loss of 
gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med. 
6(7), e1000107 (2009).
 17. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic 
immune activation in chronic HIV infection. Nat Med. 12, 1365-1371 (2006).
 18. Lempicki RA, Kovacs JA, Baseler MW, et al. Impact of HIV-1 infection and highly active 
antiretroviral therapy on the kinetics of CD4+ and CD8+ T cell turnover in HIV-infected 
patients. Proc Natl Acad Sci USA. 97, 13778–13783 (2000).
 19. Titanji K, De Milito A, Cagigi A, et al. Loss of memory B cells impairs maintenance of 
long-term serologic memory during HIV-1 infection. Blood. 108,1580-1587 (2006).
 20. Thacker TC, Zhou X, Estes JD, et al. Follicular dendritic cells and human immunodeficiency 
virus type 1 transcription in CD4+ T cells. J Virol. 83(1), 150-158 (2009).
 21. Racz P, Tenner-Racz K, van Vloten F, et al. Lymphatic tissue changes in AIDS and other 
retrovirus infections: tools and insights. Lymphology. 23, 85-91 (1990).
 22. Siegrist C-A: Vaccine immunology. In: Vaccines (fith edition). Plotkin SA, Orenstein WA, 
Offit PA (Ed.), Saunders Elsevier Inc., Philadelphia, USA, 17-36 (2008).
 23. Lederman MM, Valdez H. Immune restoration with antiretroviral therapies – Implications 
for clinical management. JAMA. 284, 223–228 (2000).
 24. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among 
patients with advanced human immunodeficiency virus infection. N Engl J Med. 338, 853-
860 (1998).
 25. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in 
patients infected with HIV-1. Lancet. 352, 1725-1730 (1998).
 26. Elrefaei M, McElroy MD, Preas CP, et al. Central memory CD4+ T cell responses in chronic 
HIV infection are not restored by antiretroviral therapy. J Immunol. 173, 2184-2189 (2004).
 27. Smith K, Aga E, Bosch RJ, et al. Long-term changes in circulating CD4 T lymphocytes in 
virologically suppressed patients after 6 years of highly active antiretroviral therapy. AIDS. 
18(14), 1953-1956 (2004).
 28. Valdez H, Smith KY, Landay A, et al. Response to immunization with recall and neoantigens 
after prolonged administration of an HIV-1 protease inhibitor-containing regimen. AIDS. 
14, 11-21 (2000).
 29. Gelinck LB, van den Bemt BJ, Marijt WA, et al. Intradermal influenza vaccination in immu-
nocompromised patients is immunogenic and feasible. Vaccine. 27(18), 2469-2474 (2009).
 30. Klein MB, Lu Y, DelBalso L, Coté S, Boivin G. Influenzavirus infection is a primary cause of 
febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis. 45(2), 
234-240 (2007).
 31. Watera C, Nakiyingi J, Miiro G, et al. 23-Valent pneumococcal polysaccharide vaccine in 
HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS. 18(8),1210-
1213 (2004).
 32. Kitahata MM, Gange SJ, Abraham AG, et al.; NA-ACCORD Investigators. Effect of early 










































 33. Gelinck LB, Van der Ende ME. Early versus deferred antiretroviral therapy for HIV. N Engl 
J Med. 361(8): 823 (2009).
 34. When To Start Consortium. Timing of initiation of antiretroviral therapy in AIDS-free HIV-
1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 373(9672), 
1352-1363 (2009).
 35. Gelinck LB, Jol-van der Zijde CM, Jansen-Hoogendijk AM, et al. Restoration of the anti-
body response upon rabies vaccination in HIV-infected patients treated with HAART. AIDS. 
Accepted for publication. (2009).
 36. Overton ET. An overview of vaccinations in HIV. Curr HIV/AIDS Rep. 4(3), 105-113 
(2007).
 37. Madhi S, Maskew M, Koen A, et al. Efficacy of influenza vaccine in HIV-nfected (HIV+) 
adults: a double-blind, placebo randomized controlled trial in South Africa. Presented at: 
5th Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, 
19-22 July 2009 (2009).
 38. Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies 
with one or two doses of influenza vaccine: a randomised study. Br J Haematol. 130(1), 
96-98 (2005).
 39. Magnani G, Falchetti E, Pollini G, et al. Safety and efficacy of two types of influenza vaccina-
tion in heart transplant recipients: a prospective randomised controlled study. J Heart Lung 
Transplant. 24(5), 588-592 (2005).
 40. O’Hagan DT. Recent advances in vaccine adjuvants for systemic and mucosal administra-
tion. J Pharm Pharmacol. 50(1),1-10 (1998).
 41. Souayah N, Nasar A, Suri MF, Qureshi AI. Guillain-Barre syndrome after vaccination in 
United States a report from the CDC/FDA Vaccine Adverse Event Reporting System. Vac-
cine. 25(29), 5253-5255 (2007).
 42. Juurlink DN, Stukel TA, Kwong J, et al. Guillain-Barré syndrome after influenza vaccination 
in adults: a population-based study. Arch Intern Med. 166(20), 2217-2221 (2006).
 43. Kroon FP, Beersma MF, Kroes AC, Groeneveld PH, van Dissel JT. Vaccination and HIV-1 
replication during highly active antiretroviral therapy. AIDS. 13(1), 135-136 (1999).
 44. Sullivan PS, Hanson DL, Dworkin MS, Jones JL, Ward JW; Adult and Adolescent Spectrum 
of HIV Disease Investigators. Effect of influenza vaccination on disease progression among 
HIV-infected persons. AIDS. 14(17), 2781-2785 (2000).
 45. Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow 
fever vaccination in a case with HIV infection. J. Med Assoc Thai. 85, 131-134 (2002).
 46. Tasker SA, Schnepf GA, Lim M et al. Unintended smallpox vaccination of HIV-1-infected 
individuals in the United States military. Clin Infect Dis. 38, 1320–1322 (2004).
 47. Redfield RR, Wright DC, James WD, Jones TS, Brown C, Burke DS. Disseminated vaccinia 
in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med 316, 
673–676 (1987).
 48. Centers for Disease Control and Prevention. Measles pneumonitis following Measles-
Mumps-Rubella vaccination of a patient with HIV infection, 1993. Morbid Mortal Wkly 
Rep. 45, 603–606 (1996).
 49. Bannister C, Bennett L, Carville A, Azzopardi P. Evidence behind the WHO guidelines: 
hospital care for children: what is the evidence that BCG vaccination should not be used in 








































Vaccination of HIV-infected adults 117
 50. Nuttall JJ, Davies MA, Hussey GD, Eley BS. Bacillus Calmette-Guérin (BCG) vaccine-
induced complications in children treated with highly active antiretroviral therapy. Int J 
Infect Dis. 12(6), e99-e105 (2008).
 51. Veit O, Niedrig M, Chapuis-Taillard C, et al; Swiss HIV Cohort Study. Immunogenicity 
and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis. 48(5), 
659-666 (2009).
 52. Lim JK, Louie CY, Glaser C, et al. Genetic deficiency of chemokine receptor CCR5 is a 
strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in 
the US epidemic. J Infect Dis. 197(2), 262-265 (2008).
 53. Pulendran B, Miller J, Querec TD, et al. Case of yellow fever vaccine--associated viscerotropic 
disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in 
CCR5 and RANTES genes. J Infect Dis. 198(4), 500-507 (2008).
 54. Roukens AH, Visser LG, Kroon FP. A note of caution on yellow fever vaccination during 
maraviroc treatment: a hypothesis on a potential dangerous interaction. AIDS. 23(4), 542-
543 (2009).
 55. Conesa-Botella A, Colebunders R. Response to “Case of yellow fever vaccine-associated 
viscerotropic disease with prolonged viremia, robust adaptive immune responses, and poly-
morphisms in CCR5 and RANTES genes”. J Infect Dis. 199(4), 601 (2009).
 56. Arribas López JR. Secondary effects of treatment with maraviroc and other CCR5 antago-
nists. Potential impact of the CCR5 blocker. Enferm Infecc Microbiol Clin. 26 Suppl 11, 
23-27 (2008).
 57. Telenti A. Safety concerns about CCR5 as an antiviral target. Curr Opin HIV AIDS. 4(2), 
131-135 (2009).
 58. Moss WJ, Halsey NA. Vaccination of human immunodeficiency virus-infected persons. In: 
Vaccines (fith edition). Plotkin SA, Orenstein WA, Offit PA (Ed.), Saunders Elsevier Inc., 
Philadelphia, USA, 1-16 (2008).
 59. Pickering LK, Baker CJ, Freed GL, et al. Immunization Programs for Infants, Children, 
Adolescents, and Adults: Clinical Practice Guidelines by the Infectious Diseases Society of 
America. Clin Infect Dis. Epub ahead of print (August 6, 2009).
 60. Bailey CL, Smith V, Sands M. Hepatitis B vaccine: a seven-year study of adherence to the im-
munization guidelines and efficacy in HIV-1-positive adults. Int J Infect Dis. 12(6), e77-e83 
(2008).
 61. CDC. Swine influenza A (H1N1) infection in two children---Southern California, March--
April 2009. Morb Mortal Wkly Rep. 58, 400-402 (2009).
 62. Kelly H, Grant K. Interim analysis of pandemic influenza (H1N1) 2009 in Australia: surveil-
lance trends, age of infection and effectiveness of seasonal vaccination. Euro Surveill. 14(31), 
pii:19288 (2009).
 63. Centers for Disease Control and Prevention (CDC). 2009 pandemic influenza A (H1N1) 
virus infections - Chicago, Illinois, April-July 2009. Morb Mortal Wkly Rep. 58(33), 913-
918 (2009).
 64. Centers for Disease Control and Prevention (CDC). Serum cross-reactive antibody response 
to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. Morb 
Mortal Wkly Rep. 58(19), 521-524 (2009).
 65. Itoh Y, Shinya K, Kiso M, et al. In vitro and in vivo characterization of new swine-origin 









































 66. National Center for Immunization and Respiratory Diseases; Centers for Disease Control 
and Prevention (CDC). Use of influenza A (H1N1) 2009 monovalent vaccine: recom-
mendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR 














































Dept. of Infectious Diseases, Leiden University Medical Center (LUMC), Leiden and 















































































Summary and general discussion 121
IntroductIon
Patients with an impaired immunity, either due to the use of immunosuppressive medica-
tion, chronic HIV infection or a hematologic stem cell transplantation, are at a greater risk 
of developing (opportunistic) infections. [1-4] The consequences of infections often are 
more severe in immunocompromised patients as compared to healthy individuals. [5-8] 
Both pneumococcal and influenza infections are associated with greater morbidity and 
mortality in immunocompromised patients. [9-12] The impact of these two infections 
can be reduced by vaccinating these patient groups, as advised by many international 
guidelines. [13,14] However, the response upon vaccination is typically reduced in these 
patients, due to the impaired immunity. [15,16]
In order to study different parts of the immune system we investigated the response upon 
T-cell-independent (pneumococcal polysaccharide), T-cell-dependent (influenza) and 
T-cell-dependent neo antigen (rabies) vaccines in several types of immunocompromised 
patients.
Several aspects of the immune response have been evaluated.
summary
Chapter 1 and 2 resulted from the ‘vaccination Response in ImmunoCompromised Hosts 
1 (RICH1)’ study, conducted in 2003/04; chapters 3, 4 and 5 resulted from the RICH2 
study, conducted in 2005/06. The first three chapters of this thesis report on the results of 
studies conducted in patients treated with relatively new immune modulating medication.
In Chapter 1 the effect of anti-TNF with or without other immunosuppressive medica-
tion on the antibody response upon the 23 valent pneumococcal polysaccharide (PPS23) 
vaccine is described. The antigens included in this vaccine initiate a T-cell-independent 
immune response, although partial and non-specific dependency of T-cells has been de-
scribed for some of the antigens included in the vaccine. A true T-cell response, however, 
(including the forming of memory cells) is not induced. In a mixed population of patients 
with rheumatic diseases and inflammatory bowel disease we found that the combination 
of methotrexate with anti-TNF was a potent inhibitor of the immune response. This 
synergy between methotrexate and anti-TNF was also observed in several clinical studies 
on the treatment of RA. [17] However, the underlying pathophysiological pathway has 
not been elucidated.
Chapter 2 describes the response upon the T-cell-dependent influenza vaccine in the 








































122 Summary and general discussion
lar pathogens (such as mycobacteriae) seen in patients treated with anti-TNF, is suggestive 
of an impaired T-cell mediated immunity. We demonstrated that anti-TNF modestly but 
significantly inhibits the response upon the T-cell-dependent influenza vaccine. Unlike the 
response upon the T-cell-independent PPS23 vaccine, the combination of methotrexate 
with anti-TNF did not further enhance the impaired immune response upon influenza 
vaccination as compared to anti-TNF alone.
The results from the RICH1 study show that anti-TNF inhibits cellular immunity. 
Only when anti-TNF is combined with methotrexate, there is an additional inhibition 
of the T-cell-independent response. The synergy of anti-TNF and methotrexate is unique 
for the T-cell-independent immunity and not present in the T-cell-dependent immune 
response. The synergistic effect of anti-TNF and methotrexate thus most likely interferes 
with specific B-cell processes such as B-cell-receptor-antigen binding and signalling, 
processes that have been shown to be TNF-dependent. This finding shows insight into 
the mechanism of the synergy between these two drugs in the treatment of RA. The 
synergy observed in therapeutic trials might thus very well be attributed to the effect 
on the T-cell-independent (humoral) immunity. Inhibition of humoral immunity is a 
relatively novel concept in the treatment of RA, although ‘old’ drugs like sulfasalazine (and 
its metabolites) also have been shown to inhibit B-cell immunity.
In the Appendix to chapter 1 and 2 additional data from the RICH1 study are shown, 
such as data from the week 8 follow up and the fact that the antibody response upon 
the T-cell-independent pneumococcal polysaccharides and the T-cell-dependent influenza 
hemagglutinin are independent of each other, representing distinct immunological path-
ways as illustrated in Figure 1.
In Chapter 3 we evaluated the response upon influenza vaccination in RA patients 
treated with the specific anti-B-cell therapy, rituximab. Rituximab is now a common 
treatment option in patients failing anti-TNF therapy. In 2005, when this study was 
conducted, this still was an experimental treatment for RA patients, limiting the number 
of patients that could be included in this study group.
Nonetheless, we found a clear and significant inhibition of the antibody response 3 
months after two rituximab infusions, with a low B-cell count at the time of vaccination. 
This study shows that a depleted B-cell number interferes with antibody production, 
which is the final common pathway of both T-cell-dependent and T-cell-independent 
immune responses.
Chapter 4 explores a possibility to enhance influenza vaccination outcomes in patients 
with an impaired immunity. On theoretical grounds we expected a more efficient anti-
gen processing, possibly resulting in higher post vaccination antibody titers, when the 
influenza vaccine would be delivered intradermal as compared to the routine practice of 
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faster and larger T-cell response in the draining lymph nodes as compared to traditional 
intramuscular vaccination. Recently, the superiority of intradermal vaccination has also 
been shown in humans.
We used a reduced dose (one fifth) of a trivalent subunit influenza vaccine for intra-
dermal vaccination, in several groups of immunocompromised patients to exploit the 
superior immunological properties of the dermis. We found that a reduced dose intrader-
mal vaccination elicited equal titers as compared to full dose intramuscular vaccination in 
healthy controls, rheumatologic patients treated with anti-TNF, HIV-infected individuals 
and hematologic stem cell transplant patients. A third study arm with the reduced dose 
(0.1 mL) intramuscular would have been a relevant comparator to truly compare the 
immunological properties of the dermis and the muscle. However, since there is a clear 
dose-response relation between the amount of vaccine administered and the subsequent 
antibody response, it was deemed unethical to administer a subtherapeutic dose intramus-
cular. The finding that a lower dose (when administered intradermal) can be as effective as 
regular full dose vaccination is both of immunological and clinical significance. Vaccine 
shortages often occur, illustrated by the fact that there was an actual influenza vaccine 
shortage in The Netherlands in the year this study was conducted (2005). Using vaccine 
antigens in a more efficient way could aid in resolving these shortages.
Local skin reactions upon intradermal vaccination proved to be predictive of the 
humoral immune response. Non-responders (a protective titer against zero out of three 
antigens) were identified by the absence of a skin reaction with a sensitivity of 83% but 


























Figure 1. Antibody response (geometric mean titer) upon T-cell-dependent influenza (A/H3N2) and T-cell-
independent pneumococcal polysaccharide (PPS9V) antigens within the same patient groups (RICH1 








































124 Summary and general discussion
antigens) were even less accurately identified by the occurrence of a skin reaction (sensitiv-
ity 60%, specificity 65%). Still, the relatively high sensitivity of the absence of a local skin 
reaction upon intradermal vaccination in immunocompromised patients could be useful 
in a clinical strategy to optimize the immune response: administering a second influenza 
vaccination after four weeks, only in those who do not develop a skin reaction upon intra-
dermal vaccination. Repeated vaccination at week 4 increased the proportion of subjects 
that were protected to at least one or two of the vaccine antigens in this subgroup (Figure 
2). In immunocompromised patients who did develop a skin reaction upon intradermal 
vaccination (52% of all immunocompromised patients), we found no additional gain 
in the percentage of patients with a protective titer after repeated vaccination at week 4 
(Figure 2).
In the Appendix to chapter 3 and 4 additional data of the RICH2 study are presented. 
These include the follow up up to week 26 and more detail on the intradermal vaccination 
and local adverse reactions.
In Chapter 5 we investigated the forming of cross-reactive anti-influenza antibodies, a 
clinically desirable effect, upon influenza vaccination, in immunocompromised patients. 
Antibodies elicited by natural influenza infection or by vaccination show some cross-
reactivity against different influenza strains. With increasing antigenic differences between 
different strains (the so called antigenic distance) the likelihood of cross-reactivity de-
creases. [18-19] This cross-reactivity is of clinical value in times when there is a mismatch 
between the influenza strain included in the vaccine and the circulating strain, a phenom-
enon known to occur with some regularity. It was shown before that elderly (≥75 years of 
age) are more at risk for influenza-infection in times of a strain mismatch, due to poorer 
cross-reactive properties of the antibodies elicited by vaccination.
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Figure 2. Number of antigens upon which a protective titer was formed four weeks after influenza 
vaccination (t=4) and four weeks after booster vaccination (t=8) in a group with and a group without a 
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We re-tested the samples from the RICH2 study cohort (as described in chapter 4) for 
the ability to react to the homologue (vaccine) strain and the cross-reactivity against drift 
variants that appeared in the subsequent years. We found that cross-reactive titers waned 
with increasing antigenic distance, as expected. The cross-reactive properties of antibodies 
in healthy controls were similar as compared to those in HIV-infected individuals.
This finding suggests that the mechanism that causes the impaired cross-reactivity in 
the elderly differs from the immune defects found in HIV-infected individuals (with a 
mean CD4-cell count of 440 cells / μL).
In Chapter 6 we describe a cohort of HIV-infected individuals, many of them survivors 
of the pre-HAART era with CD4 T-lymphocyte nadir counts well below 200 cells per 
μL, before HAART was initiated, who were followed for almost a decade. These patients 
were, after a mean of 41 months of HIV treatment, vaccinated twice with the rabies 
vaccine, a T-cell-dependent neo-antigen, so that both the primary and booster response 
could be investigated. At the time of vaccination a successful quantitative immune res-
toration was reached, in almost all patients, with a median CD4 T-lymphocyte count of 
537 (interquartile range 353-772) cells per μL. Even though the overall post vaccination 
titers were lower in HIV-infected individuals as compared to healthy controls, all T-cell-
dependent processes studied operated in a functional matter. A true booster response, an 
IgM to IgG antibody class switch and avidity maturation were present in the HIV-infected 
individuals, despite low T-lymphocyte numbers before initiating HAART. Five years after 
vaccination, two thirds of the HIV infected patients still had antibody titers above the 
protection threshold as defined by the World Health Organisation.
This study suggests that the initiation of anti-retroviral therapy in HIV-infected indi-
viduals not only gives rise to a quantitative but, more importantly, to a qualitative immune 
restoration. The complex interplay of antigen, antigen-presenting cells, cytokines and both 
T- and B-lymphocytes, which has been shown to be disrupted in progressive HIV-disease, 
appears to recover to a functional level after initiation of antiretroviral therapy. However, 
even after more than 3 years of anti-retroviral therapy, this recovery is less than complete.
The general principles of vaccination in HIV-infected adults, illustrated with collated data 
from the RICH2 study, are reviewed in Chapter 7. The use of live vaccines and medica-
tion interactions in HIV-infected individuals are being considered. A comment is made 








































126 Summary and general discussion
General dIscussIon
The quantity and quality of the immune response in immunocompromised hosts
In the studies described in this thesis, we used vaccinations to measure several aspects of 
the qualitative and quantitative immune response in patients with an impaired immunity.
The fact that anti-TNF inhibits the T-cell-dependent but not the T-cell-independent 
response upon vaccination, clearly classifies anti-TNF as an inhibitor of the T-cell medi-
ated immune response, as would be expected. Exploring the mode of action of anti-TNF 
is relevant for the understanding of the pathophysiology of e.g. rheumatoid arthritis and 
subsequently for the development of even more specific immune modulating drugs. The 
observations from vaccination studies add information to clinical studies, that show the 
efficacy of these drugs as disease modifying drugs, without elucidating the mode of action. 
[20-22] Our findings are in line with the surplus of opportunistic infections found in 
patients treated with anti-TNF. [23-25] These infections are mainly caused by pathogens 
such as intracellular bacteriae (mycobacteriae, Listeria, salmonellae) and yeasts (crypto-
cocci, histoplasma), which are associated with failing T-cell immunity. [26]
The finding that the combination of anti-TNF with methotrexate ‘broadens’ the im-
mune suppressive effect to include B-cell inhibition is a novel finding. Both rituximab 
and the combination methotrexate and anti-TNF inhibit B-cell responses. However, their 
mechanisms of action are quite different. Rituximab depletes CD20+ B-cells which are 
the progenitors of antibody producing (plasma-)cells, and thus inhibits the final common 
pathway of both T-cell-dependent and -independent immune responses. [27-30] The 
combination of anti-TNF with methotrexate shows a synergistic inhibitory action only on 
the T-cell-independent immune response, pinpointing its effect on ‘early’ B-cell processes 
(before the final common pathway of T-cell-dependent and independent responses), such 
as antigen-B-cell binding and the subsequent signalling. [31] This is in line with the 
original concept of adding methotrexate to anti-TNF therapy to inhibit the forming 
of antibodies directed against these drugs. Recent pathophysiological insights and drug 
developments have concentrated on several other aspects of the B-cell involvement in 
the (pathological) immune response. Blocking the B-cell activating factor belonging to 
the tumor necrosis factor (TNF) family (BAFF), also known as B-lymphocyte stimulator 
(BLyS), has been evaluated in the treatment of SLE. [32,33] BAFF and its receptor, trans-
membrane activator and calcium modulator ligand interactor (TACI), are upregulated 
by ligation of toll-like receptors and by interferons, providing a link with pathogens or 
vaccine antigens. BAFF deficient mice show immune responses comparable with those 
found in patients treated with the combination of anti-TNF and methotrexate with a 
greater impairment of T-cell-independent than T-cell-dependent responses upon vaccina-
tion. [34-36] Figure 3 is a schematic representation of the possible mechanisms by which 








































Summary and general discussion 127
By evaluating several patients groups within the same vaccination protocol we found a 
clear hierarchy within the different groups, thus applying influenza vaccination as a tool 
to measure the severity of the immunodeficiency. This is a feasible strategy which could 
be employed in drug development trials, that evaluate the effect of immune modulating 
medication, to predict the extent of the immunosuppressive effect of these newer drugs. 
For drugs such as imatinib, a tyrosine kinase inhibitor, for example, the extent and the 












































Figure 3. Schematic representation of the mode of action of methotrexate (MTX), anti-TNF and rituximab 
in their inhibition of the immune response upon vaccination.
a. The combination of MTX with anti-TNF specifically inhibits the T-cell-independent and not T-cell-
dependent immune response. B-cell-Antigen binding and subsequent signalling have been shown to 
be TNF dependent. Combined with the suppression of B-cell function and the subsequent inhibition 
of antibody production by methotrexate, this might create a specific B-cell defect, beneficial for the 
treatment of RA but simultaneously leading to impaired immune responses upon polysaccharide 
exposure. (chapter 1)
b.The interaction of antigen-presenting cells and T-cells and the subsequent augmentation of the 
immune response upon a presented antigen is mediated in part through the action of TNFα. It is likely 
that anti-TNF inhibits this augmentation of the T-cell-dependent immune response (chapter 2).
c. Rituximab depletes CD20+ B-cells, either through complement-mediated cytotoxicity, antibody-
dependent cell-mediated cytotoxicity or apoptotic or antiproliferative effects. This results in a severely 
hampered immune response upon neo-antigens (chapter 3). In this thesis we tested only the T-cell-
dependent pathway. Since rituximab affects the common pathway of both T-cell-dependent and 
independent immune responses, it is highly likely that it also blocks the response upon a polysaccharide.








































128 Summary and general discussion
with the growing use of this drug, case reports of tuberculosis possibly related to the use 
of this drug appear in the literature. [37-39] Evaluating the response upon (influenza) 
vaccination in patients on chronic imatinib therapy might shed some light on the extend 
of the immune deficiency. There are some clear disadvantages in the use of the influenza 
vaccine, such as the fact that the vaccine is updated annually; that global uniform outcome 
measurements are lacking and interference of possible confounders as described below. 
However, these disadvantages are outweighed by the fact that influenza vaccination can be 
used repeatedly, is inexpensive, easy to administer, safe, widely available and is indicated 
in immunocompromised patients. A T-cell-dependent neo-antigen, such as the rabies 
vaccine, allows for a more extensive evaluation of various aspects of the T-cell-dependent 
immune response, as shown in HIV-infected individuals (chapter 6). However, evaluating 
immune responses upon rabies vaccination is logistically more difficult and the individual 
responses upon the rabies vaccine are more variable as compared to the response upon 
influenza vaccination.
Additional determinants of the immune response
Age
Overall the antibody response diminishes with rising age. Although the three study 
cohorts described in this thesis (RICH1, RICH2 and rabies) were relatively young, this 
phenomenon was found in all three cohorts. Age proved to be a confounding factor in 
the rabies vaccination study, were the healthy controls were considerable younger than the 
HIV-infected individuals. The primary immune response, significantly impaired in HIV-
infected individuals in a univariate analysis, proved to be statistically indistinguishable 
from that of healthy controls after adjustment for age.
The absolute number of naïve (CD4 and CD45RA positive) T-cells was inversely 
correlated with age (Figure 4). Diminishing thymus size and, secondary to this process, 
decreasing naïve T-cell numbers are physiologic aging processes. [40,41] Immune recovery 
after starting HAART in HIV-infected individuals is better at a younger age. [42,43] 
Many other factors have been described that might be correlated with this so called im-
munosenescence. [44] In the rabies study we found that higher age (in the setting of a low 
CD4 cell nadir before initiating HAART) was the most important factor, compromising 
the primary immune response upon vaccination with a T-cell-dependent neo-antigen, 
even after immune reconstitution as measured by a total CD4 cell count. In contrast, the 
booster response in these HIV-infected individuals was inhibited by the immunodeficiency 
and not by higher age. These data suggest that the age effect, found in numerous vaccina-
tion studies, most likely acts primarily through a compromised number of naïve T-cells, 
which are pivotal cells in the immune response upon a neo antigen. Age adjustments were 








































Summary and general discussion 129
Previous exposure
Previous exposure to the vaccine antigen is relevant in all vaccination trials. Prevaccination 
titers are generally higher in patients who are vaccinated before. Furthermore, relatively 
high anti-influenza titers may persist for a long time after developing influenza, even if the 
disease course was mild and not recognized as ‘the flu’ by the individual. In the RICH1 
study, for example, already 70% of the healthy controls had antibodies against the A/
H3N2 vaccine strain, even though only one (6%) of them was vaccinated before (Figure 
5). Repeated exposure to an identical antigen, will typically lead to an exponential titer 
increase (booster response) as shown in the rabies study. [chapter 6, this thesis] Previous 
influenza vaccination thus can act as an important confounding factor in determining vac-
cination outcomes and should be addressed in every influenza vaccination study. In Figure 
6 the study outcomes (geometric mean anti-influenza titers) are represented based on 
whether the subject was vaccinated before (within pooled intramuscular and intradermal 
study groups). In some, but not all, experiments we found lower post vaccination titers 
in subjects with a history of previous vaccination, even when that vaccine antigen was 
identical to the one administered the year before. This counter intuitive outcome has 
been described before and was named ‘the Hoskins’ paradox’ after the author of multiple 
influenza vaccination studies in the early 1970s. [45-47] Influenza vaccination is more 
complex than for instance rabies vaccination, since antigens are adapted on an annual 
basis, to match circulating strains. As shown in chapter 5 significant cross-reactivity does 
occur between related strains. Two processes might play a role in the paradoxal lower post 
vaccination titers in previously vaccinated subjects: 1. neutralisation of vaccine antigen 
(or the forming of immune complexes) by circulating antibodies and 2. a phenomenon 
know as the ‘original antigenic sin’ which means that a related antigen will boost the 
response upon the original antigen, as opposed to the newly administered antigen, when 
there is enough resemblance. This latter process may play a role in the findings of the 
RICH1 study (since higher prevaccination titers per se were not associated with lower 





























































Figure 4. Correlation of the number of naïve (CD4+CD45RA+) T-lymphocytes with respectively age (panel 
A, Pearson correlation: r=-0.55 , p<0.005) and the IgG antibody response at week 4 after rabies vaccination 
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Figure 5. Prevaccination geometric mean titers against influenza A/H3N2, A/H1N1 and influenza B based 
on whether patients were previously vaccinated or not (pooled data from intramuscular and intradermal 
vaccination route, RICH2 study). Titers from previously vaccinated subjects also represent vaccination 
titers one year after influenza vaccination. Closed black symbols: not previously vaccinated; open grey 
symbols: previously vaccinated.
*p<0.05; ** p≤0.001, comparisons only made within each study group.
(>) vaccine antigen different from antigen included in vaccine from previous season;
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Figure 6. Postvaccination geometric mean titers against influenza A/H3N2, A/H1N1 and influenza B based 
on whether patients were previously vaccinated or not (pooled data from intramuscular and intradermal 
vaccination route, RICH2 study).
Closed black symbols: not previously vaccinated; open grey symbols: previously vaccinated.
*p<0.05; ** p≤0.001, comparisons only made within each study group.
(>) vaccine antigen different from antigen included in vaccine from previous season;
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explanation). The amount of vaccine used or the vaccination route did not influence the 
magnitude of this effect in the RICH2 study.
In the studies presented in this thesis adjustments (for either previous vaccination; 
the prevaccination titer or the interaction product of these two factors) were done where 
applicable.
Gender and other factors
Gender has been reported in some vaccination studies as a relevant factor for which 
adjustment was necessary. Both male and female gender have been correlated with better 
outcomes in different studies. [48, 49] In none of our studies, gender proved to be a 
relevant factor of influence on the antibody response. Figure 7 shows the vaccination 
results from the RICH1 and RICH2 study (geometric mean titers against influenza A/
H3N2) divided by gender instead of immunization route.
Many other factors have been implied as variables that influence the outcome upon vac-
cination: among them the site of vaccine administration (e.g. deltoid vs. gluteal muscle), 
body weight, smoking, blood (ABO) group and zidovudine, statin or cotrimoxazole use. 
[50,51] These factors were not evaluated in our vaccination trials, although the route and 
place of vaccination were fixed and statin use was rare. The (permuted-block) random-

















Figure 7. Postvaccination geometric mean titers against influenza A/H3N2 based on gender (pooled data 
from intramuscular and intradermal vaccination route, RICH2 study).
Closed black symbols: female; open grey symbols: male.
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The immunology of antibody production
Two additional factors are important to realize when interpreting the data from our studies. 
First, all outcome measurements (mainly antibody titers) used in this thesis are surrogate 
parameters. True vaccine efficacy is established in large trials, to be able to determine a 
protective effect on morbidity or mortality. [52] However, the study outcomes used in this 
thesis have been correlated with clinical efficacy and geometric mean titers are suitable for 
the comparison of groups, irrespective of the clinical effect. [53-55]
Second, measuring antibody responses as a readout of the immune response, as was 
done in the studies presented in this thesis, is a simplification of the immunological real-
ity. The immune response is far more complex than only antibody production, involving 
many aspects of both innate and adaptive immunity, including cellular responses. In 
between the administration of the vaccine and measuring the antibody level four weeks 
later is an ‘immunological black box’. Both primary and secondary immune responses 
take place in lymphoid tissue and the physiology of this response upon vaccination is 
reasonably well described in healthy subjects. B-cell activation upon antigen binding will 
upregulate CCR7, a molecule that will drive antigen-specific B-cells to the outer T-cell 
zone of lymphoid tissues. Antigen-specific B-cells are captured and retained by follicular 
dendritic cells (FDCs) that, in cooperation with follicular T-cells, facilitate massive clonal 
proliferation. The class switch from IgM to IgG, IgA or IgE secreting plasma cells and 
affinity maturation will take place in the germinal centers (GC) that are formed upon 
this proliferation. In a high turnover state the B-cell with the highest affinity for the 
vaccine antigen will take that antigen from the FDCs, process this antigen and undergo 
subsequent T-cell help for proliferation. Less specific cells will degrade in this process. 
This process, also known as the somatic hypermutation process, will drive the response 
towards the most specific antibody producing cells. In healthy subjects, the forming of a 
GC reaction takes about 2 weeks, negative feedback starts within 3-6 weeks, thus peak 
IgG levels can be found 4-6 weeks after primary vaccination. Although direct in situ 
measurements were not conducted in the studies presented in this thesis and B- and T-cell 
numbers were only determined in peripheral blood, our studies allow for some specula-
tions on what happens in ‘the immunological black box’ as described above. The rabies 
vaccination study (chapter 6, this thesis) illustrates that GC forming takes place in both 
healthy controls and HIV-infected individuals. In HIV-infected individuals the lymph 
node architecture is largely destroyed by the immune activation that characterizes chronic 
HIV-infection. Most HIV-infected individuals who participated in this study started with 
HAART as soon as this therapy became available, the majority of these patients had CD4 
counts below 200 cells/μL at that time point. From historical vaccination studies we know 
that the T-cell-dependent immune response is severely compromised in patients with such 
a severe immune deficiency. [56,57] The fact that all processes of the T-cell mediated 
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study cohort described in chapter 6 is a strong indicator that the initiation of HAART 
leads to both quantitative and qualitative immune reconstitution. However, a minority of 
the HIV-infected individuals and none of the healthy controls showed a delayed response 
upon primary rabies vaccination (data not shown), which might be a clue that GC form-
ing in HIV-infected individuals is indeed less efficient.
Whereas in HIV-infection the number of CD4+ T-lymphocytes is decreased and the 
architecture of the lymph nodes disrupted, patients treated with anti-TNF have a different 
kind of immune deficiency. TNFα is a versatile cytokine with many functions, one of 
them being a crucial cytokine in augmenting the Th1-type (pro-inflammatory) immune 
response. Antigen presenting cells (APCs) secrete TNFα upon antigen binding, which 
attracts and stimulates T-cells that produce interferon gamma, which in turn stimulates 
the APCs. B-cell proliferation is dependent on this process. Antagonizing TNF likely in-
terferes with the augmentation of the immune response, thus impairing T-cell-dependent 
immune responses.
The positive correlation between (the absence of ) a local inflammatory response upon 
intradermal vaccination and the (lack of a) subsequent immune response might be a reflec-
tion of the physiology of the immune response upon vaccination. Immature dendritic cells 
internalize vaccine antigens and are subsequently activated by the local inflammation, 
which is classically caused by the vaccine adjuvants. The absence of a local inflamma-
tory response can thus contribute to an impaired immune response. The fact that local 
inflammatory reactions in general are largely TNF-alpha driven possibly contributes to the 
inhibitory effect of anti-TNF on the immune response upon vaccination.
Longevity of the immune response in immunocompromised hosts
The longevity is a third aspect of the immune response in immunocompromised patients, 
besides the quantity and quality, which is often reported as being inferior to that of 
healthy controls. [58] Follicular B-helper (CXCR5+) T-cells (TFH-cells) are thought to be 
the pivotal cells for the development of memory B-cells. Although CXCR5 can not act 
as a co-receptor for HIV cell entry, the dependency of T-cells for the forming of B-cell 
memory, combined with the known T-cell dysfunction in HIV might provide a model 
for the shorter lasting immunity found in HIV-infected individuals. [59-61] Another 
explanation might be the impaired B-cell function described in HIV-infected individuals, 
which is already apparent directly after primary infection. Circulating memory B cells are 
severely reduced in the peripheral blood of (both acute and chronically) HIV-1-infected 
patients, which impairs maintenance of long-term serologic immunity to HIV-1-unrelated 
antigens. This defect appears not to be restored upon HIV treatment. [62,63]
In the rabies vaccination study we were able to follow up all patients five years after 
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(geometric mean) peak values four weeks after booster vaccination, remained above the 
protection threshold for a shorter period as compared to healthy controls. Still, the major-
ity of HIV-infected individuals had a titer above the protection threshold five years after 
vaccination. Subjects with the highest titers four weeks after the booster vaccination were 
more likely to be protected five years later.
Patients on anti-TNF (and rituximab) therapy, who received influenza vaccination 
before, showed remarkably low prevaccination titers (as rest-titer one year after the previ-
ous vaccination), even if the vaccine antigen had remained unchanged, indicating a short 
lasting response in these patients (Figure 5). The low anti-influenza titers 1 year after 
vaccination in patients treated with anti-TNF indicate that antagonizing TNF interacts 
with the forming of memory B- and T-cell clones. This is conceivable since TNFα is, as 
stated before, a critical cytokine in augmenting the T-cell-dependent immune response, 
both on the site of antigen delivery as in de GC.
In the RICH2 study we analyzed samples taken six months after vaccination. The titers 
at this time-point remained relatively stable and well above the protection threshold in 
healthy controls but not in HIV-infected individuals. This is a strong indication that the 
decreased longevity of the immune response upon vaccination in HIV-infected individu-
als is not merely the effect of lower peak values, but that titers actually decrease faster. 
This suggests that long-lived plasma cells also show a decreased survival in HIV-infected 
individuals. The 6 month follow up data from the RICH2 study can not be translated to 
the common influenza vaccination practice, because our subjects were vaccinated twice; 
the immune response after a single vaccination might well be more short lived.
These data indicate that not only the quantity of the immune response is negatively 
influenced by an impaired immunity, but also that the duration of the time above the 
protection threshold is shorter. In chapter 5 we show that the cross-reactivity of anti-
influenza antigens in HIV-infected individuals is comparable to that found in healthy 
controls, which might be of clinical benefit for protection against influenza drift variants.
A note should be made that both memory B- and T-cells might persist for decades, even 
in the absence of an antigen. These cells will promptly respond on repeated contact with 
an antigen, providing an almost instantaneous (booster) immune response. The absence of 
antibodies is thus not per se synonymous with the absence of immunity. [64]
Optimizing the immune response
As stated earlier, optimizing the immune response is most crucial for those who have a 
compromised response upon vaccination and the highest risk of disease. It seems prudent 
to postpone vaccination in HIV-infected individuals until the immunity has recovered and 
HIV-RNA suppression has fully occurred. Detectable HIV-RNA is a factor, independent 
of the CD4 cell count, that has been associated with impaired responses upon vaccina-
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and inflammation or HIV-induced apoptosis of activated T-cells involved in the immune 
response upon the vaccine antigen. [65] In the influenza study (chapter 4) the presence of 
detectable plasma HIV-RNA levels was not associated with lower postvaccination titers. 
In the rabies study only a limited number of subjects with a detectable HIV load was 
included, these subjects did however show a trend for lower postvaccination titers.
In the rabies study (chapter 6) we vaccinated subjects who were treated with antiretro-
viral treatment for a mean of 3.4 years. Whether or not immune recovery is an ongoing 
process at that time point, is unknown. It is however likely that some ‘immunological 
scars’ remain, even after a decade or more of effective antiretroviral treatment. Initiating 
anti-retroviral treatment at higher CD4 cell numbers, which has recently been shown to 
reduce the chance of AIDS and mortality, might aid in limiting the size of this scar. [66-68]
Many strategies have been explored in immunocompromised patients in order to op-
timize vaccination outcomes, including increased dosage, multiple dose vaccination, the 
use of vaccine adjuvant, immunostimulant patches and more efficient routes of vaccine 
delivery. [69-72]
We explored the latter, since the dermis is one of the best equipped organs for recognizing 
and processing antigens. The abundance of antigen presenting cells in the dermis, facili-
tates the efficient transport of (larger quantities) of antigen to the germinal centers were 
the actual immune response is formed. Both in HIV-infected individuals and in patients 
treated with anti-TNF this strategy might bypass the immune defects (as described above) 
that impair the response upon vaccination in these patients. [73-76] In healthy subjects 
some vaccines (especially adjuvants containing vaccines) give rise to a severe local inflam-
matory response with granuloma forming or even necrosis, which limits the possibilities 
to use the dermis for routine vaccination in healthy subjects.
Although in the RICH2 study intradermal vaccination did not lead to higher post 
vaccination titers, similar titers were found with a fraction of the dose administered intra-
muscular. This finding, combined with the fact that there is a dose-response relationship 
between the amount of vaccine given and the height of the post vaccination antibody 
titer strongly suggests that intradermal vaccination is more efficient. Formal proof of this 
theory was cumulated from both animal and human studies. [77-79] It is suggested that 
lower vaccine doses may result in more competition for antigen in de GCs, resulting in 
lower antibody titers that express a higher affinity. [80] Although we did not measure 
affinity, we did determine cross-reactivity of anti-influenza antibodies. More specific (high 
affinity) antibodies would be expected to show less cross-reactivity. The route (and thus 
the amount of vaccine given) did not influence the cross-reactivity in the RICH2 study; 
but the amount of antigen that is presented in the lymph node might be equal after 
low dose intradermal and regular dose intramuscular vaccination (due to more efficient 
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In both the RICH1 and 2 study we administered a second influenza vaccine dose at 
week four. The timing of this ‘booster’ vaccination might be too early to expect a true 
(logarithmic) booster response and was chosen mainly for practical reasons. On average, 
titers continued to rise after the second vaccination (Figure 1, appendix 1; Figure 3 ap-
pendix 2), although this further increase was modest and led only to a small number of 
individuals who ‘seroconverted’ only after this second vaccination. If we would have used 
the absence of a local skin reaction upon intradermal vaccination as the criterion to select 
non-responders, we would have selected the proportion (48%) that would benefit the 
most from a booster vaccination.
conclusIons and recommendatIons
Immune modulating drugs such as anti-TNF and rituximab inhibit the immune response 
upon vaccination. The inhibition of the antibody response upon influenza vaccination 
gives an indication of the severity of the (T-cell-dependent) immunodeficiency, irrespec-
tive of its mechanism. Influenza vaccination should be incorporated in industry initiated 
trials assessing immune modulating drugs, since it helps in quantifying the immune sup-
pressive potential of these drugs.
An impaired immunity strengthens, not weakens, the indication for vaccination, with the 
exemption of live attenuated vaccines. All vaccinations should preferably be administered 
before initiating or intensifying immunosuppressive therapy.
The T-cell-dependent properties of an immune response can be restored in HIV-
infected individuals treated with HAART, even when the nadir CD4 positive T-cell count 
was once below 200 cells / μL. Vaccines in HIV-infected individuals should preferably be 
administered after immune restoration and full suppression of HIV-RNA.
Intradermal influenza vaccination offers some advantages in patients with impaired im-
munity: 80% of the vaccine dose is spared without compromising the effect of the vaccine. 
The absence of a local skin reaction can be used to identify non-responders upon vaccina-
tion. These non-responders might benefit from other strategies to prevent influenza (such 
as repeated vaccination or prophylactic or pre-emptive use of antiviral medication).
Vaccination policy should be an integrated part of the care for patients with an impaired 
immunity or those about to receive immunosuppressive drugs. Adapting vaccination 
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In dit proefschrift worden vaccinatiestudies bij mensen met een verminderde afweer 
beschreven. Het doel van deze studies is niet het beschrijven van de afweerreactie sec. De 
vaccinatie studies zijn gebruikt als meetinstrument, om uitspraken te doen over het soort 
en de ernst van de verschillende afweerstoornissen. Voor nieuwe afweeronderdrukkende 
medicatie kunnen we uitspraken doen over waar deze middelen in de afweer aangrijpen en 
hoe sterk dit afweerremmende effect is. Bij mensen geïnfecteerd met het humane immu-
nodeficiëntievirus (HIV), een virus dat juist CD4-positieve T-lymfocyten aantast, kunnen 
we aan de hand van de reactie op vaccinatie uitspraken doen over allerlei onderdelen van 
die (T-cel) afweer.
De afweer
Onze afweer beschermt ons tegen invloeden van buiten, binnen de infectieziekten heten 
deze schadelijke indringers als groep pathogenen (micro-organismen die ziekte kunnen 
veroorzaken). Pathogenen worden onder andere onderverdeeld in virussen, bacteriën, 
(gisten en) schimmels en parasieten.
De menselijke afweer heeft zich ontwikkeld tot een extreem geavanceerd apparaat 
bestaande uit vele onderdelen. Binnen de mechanische barrières van de huid en de 
slijmvliezen zijn er verschillende manieren om de afweer onder te verdelen. De afweer 
laat zich bijvoorbeeld onderverdelen in een onderdeel bestaande uit cellen, de cellulaire 
afweer, en een onderdeel bestaand uit moleculen (die vaak door de afweercellen worden 
geproduceerd), de humorale afweer.
Een andere manier om de afweer in te delen is naar reactiesnelheid (en aanpassings-













aangeboren                   verworven
Figuur 1. De afweer puzzel: schematische weergave van de verschillende onderdelen van de afweer en 









































een bepaalde indringer, maar is daarmee ook weinig specifiek (de aspecifieke, aangeboren 
afweer). Dit staat tegenover een deel van de afweer dat zich aanpast aan de indringer: 
afweer op maat (de specifieke, adaptieve afweer). Dit proces kost echter tijd, soms wel 
weken, wat veel te traag is voor veel infecties die binnen dagen of zelfs uren veel schade 
kunnen geven aan hun gastheer. Een voordeel van dit type afweer is wel dat er een ge-
heugen wordt gevormd voor de specifieke pathogenen waarop ooit is gereageerd. Bij een 
hernieuwd contact met een identiek pathogeen kan er dan wel een snelle mobilisatie van 
de specifieke afweer plaatsvinden. Met name dit concept is van groot belang bij vaccinatie: 
het is (voor een aantal infectieziekten) mogelijk mensen levenslang te beschermen met 
een éénmalige vaccinatie(serie). Een schematische weergave van de afweer is afgebeeld 
in Figuur 1, waarbij de scheidslijnen tussen de verschillende onderdelen van de afweer 
overigens niet haarscherp zijn.
Vaccinatie
Het principe van vaccinatie is dat we afweer tegen een bepaald pathogeen oproepen, zonder 
dat we daarvoor die ziekte zelf hoeven door te maken. Dit kan bijvoorbeeld door alleen de 
meest afweerstimulerende onderdelen (zogenaamde antigenen) van een micro-organisme 
te gebruiken (en niet het gehele pathogeen dat ook in staat zou zijn de gastheer ziek te 
maken). Omdat hiervoor de specifieke (verworven) afweer wordt aangesproken, betreft 
het dan ook alleen afweer tegen deze geselecteerde micro-organismen. Het ’23 valente’ 
pneumokokkenvaccin, beschermt bijvoorbeeld niet tegen alle pneumokokken, maar al-
leen tegen de 23 ‘serotypen’ waarvan een stukje kapsel is opgenomen in het vaccin. De 
‘griep prik’ beschermt niet tegen alle denkbare virale luchtweg infecties, maar alleen tegen 
infecties met de specifieke influenza stammen die dat jaar in het vaccin zijn opgenomen.
De meeste vaccins werken beschermend door het oproepen van specifieke antistoffen. 
Antistoffen worden geproduceerd door plasmacellen, die weer voortkomen uit B-cellen. 
Bij T-cel-onafhankelijke vaccins kan het antigeen eigenhandig een B-cel aanzetten tot 
antistof productie tegen specifiek dat antigeen, het pneumokokkenpolysacharidevaccin is 
hier een voorbeeld van. De meeste vaccins, waaronder ook het influenza- en het rabiësvac-
cin, zijn afhankelijk van de hulp van T-cellen om een B-cel (plasmacel) aan te zetten tot 
antistof productie (Figuur 2).
Bij sommige pathogenen lukt het om met een beperkt aantal (meestal T-cel-afhankeli-
jke) vaccinaties levenslange bescherming te geven, bij andere vaccins (met name T-cel-
onafhankelijke, zoals de polysacharidevaccins) is de duur van de bescherming korter. Er 
zijn nog steeds heel veel pathogenen (waaronder HIV) waarvoor het niet is gelukt een 










































Zo divers als onze afweer zelf is, zo divers is ook het spectrum van defecten in de afweer. 
In dit proefschrift is een aantal uiteenlopende, veel voorkomende, afweerstoornissen naast 
elkaar gezet.
Er zijn ziekten die leiden tot een afweerstoornis, zoals een infectie met HIV. Als HIV 
niet behandeld wordt, zal een specifiek onderdeel van de cellulaire afweer, het aantal 
CD4-positieve T-cellen, dalen en uiteindelijk zelfs geheel verdwijnen uit het bloed. Verder 
kan het een bewuste medische manipulatie zijn om de afweer (of althans een deel daar-
van) te remmen. Dit gebeurt bij transplantaties, om te voorkomen dat het lichaam het 
transplantaat afstoot. Dit gebeurt ook bij zogenaamde auto-immuunziekten, ziekten zoals 
reumatoïde artritis (RA) of inflammatoire darmziekten (IBD), waarbij de eigen afweer 
ziekte veroorzaakt door onderdelen van het eigen lichaam abusievelijk aan te vallen. 
Auto-immuunziekten zijn daarmee de meest voorkomende reden voor het gebruik van 
afweeronderdrukkende medicatie: immuunsuppressiva. De laatste jaren zijn er belangrijke 
innovatieve ontwikkelingen, waarbij nieuwe immuunsuppressiva (zoals anti-TNF en ri-
tuximab) zeer actief blijken te zijn bij de behandeling van o.a. RA en IBD.
Vaccinatie bij mensen met een gestoorde afweer
Een afweerstoornis betekend in de praktijk ook meestal dat de afweer minder goed rea-
geert op vaccinatie (minder hoge antistof titers, kortere beschermingsduur). De kans dat 
vaccinatie dan niet tot bescherming voor die ziekte leidt neemt dan toe. In de praktijk 










































































afweerreactie is geweest na vaccinatie (en om, waar mogelijk, alternatieve maatregelen te 
treffen als er onvolledige bescherming is).
Vaccinatie is over het algemeen niet schadelijk bij mensen met een verminderde afweer. 
Alleen als er levend verzwakte vaccins worden gebruikt is er kans op ziekte veroorzaakt 
door de vaccinstam. In dit proefschrift worden geen studies met levend verzwakte vaccins 
beschreven.
samenVattInG
In Hoofdstuk 1 en 2 worden de resultaten beschreven van een vaccinatie studie die in 
2003/2004 werd uitgevoerd. We gebruikten twee verschillende soorten vaccins om van 
2 verschillende kanten te kijken naar het effect van anti-TNF bij mensen met een auto-
immuunziekte.
Het pneumokokken(polysacharide)vaccin test de T-cel-onafhankelijke afweer (hoofd-
stuk 1). Het gebruik van anti-TNF alléén geeft geen relevante remming van deze afweer-
reactie. Als anti-TNF echter gecombineerd wordt met een ander immuunsuppressivum, 
methotrexaat, wordt een sterke remming van de T-cel-onafhankelijke immuunrespons 
gezien. De combinatie van deze twee middelen bleek eerder ook al synergistisch te zijn bij 
de behandeling van RA.
In hoofdstuk 2 laten we zien dat anti-TNF wel de T-cel-afhankelijke afweerreactie 
remt. Het synergistische effect tussen anti-TNF en methotrexaat werd hier niet gezien. 
Met deze bevindingen maken we het waarschijnlijk dat ook het therapeutische effect van 
de combinatie anti-TNF en methotrexaat via het humorale (T-cel-onafhankelijke) pad 
loopt.
In de appendix bij hoofdstuk 1 en 2 wordt het vervolg na week 4 na vaccinatie ge-
toond als mede het gegeven dat de 2 verschillende vaccins gebruikt in deze studie ook 
daadwerkelijk verschillende immunologische routes testen.
In hoofdstuk 3 tonen we de reactie van RA patiënten, behandeld met rituximab, een 
krachtig B-cel onderdrukkend middel, op het influenzavaccin. Alhoewel het om slechts 4 
patiënten gaat is het overduidelijk dat rituximab een adequate antistofproductie blokkeert.
In hoofdstuk 4 beschrijven we de studie waarin wordt onderzocht of de uitkomst van 
influenzavaccinatie te verbeteren is bij verschillende groepen immuungecompromitteerde 
patiënten. Vaccins worden normaliter toegediend in een spier. Dit heeft een logistieke 
achtergrond, namelijk dat in de spier en halve milliliter vloeistof kan worden ingespoten 
met een minimale kans op complicaties. Afweercellen zijn echter niet van nature aanwezig 
in een spier en moeten worden toegevoerd via het bloed. De huid echter is doorregen 
met een fijnmazig netwerk van afweercellen dat bedoeld is om antigenen vroegtijdig op 









































het maximale volume wat in de huid is toe te dienen maar ééntiende milliliter. Dit laatste 
is een relatief nadeel, omdat een afweerreactie sterker is naarmate er meer antigeen wordt 
gegeven.
Toch bleek uit onze studie dat we met 5x minder vaccin intradermaal toegediend, we 
een gelijkwaardige afweerreactie konden oproepen vergeleken met de normale dosis in 
de spier, zowel bij de gezonde controles als bij de verschillende groepen patiënten met 
een verminderde afweer. Deze strategie kan kostenbesparend zijn en helpen om zo veel 
mogelijk mensen te beschermen als er vaccin te korten zijn (zoals het geval was voor het 
influenza vaccin in het jaar dat we deze studie uitvoerde). Intradermale toediening bleek 
in deze studie echter niet superieur aan intramusculaire vaccintoediening.
Door verschillende groepen immuungecompromitteerden in één studie te testen kon 
er een hiërarchie worden gemaakt van de ernst van de afweerstoornis binnen zo’n groep.
Een nadeel van de vaccinatie in de huid is dat dit bij de meeste mensen een lokale 
roodheid na vaccinatie geeft. Opvallend was dat deze lokale huidreactie ontbrak bij (83%) 
van de immuungecompromitteerden die geen antistoffen produceerde op (alle 3 de stam-
men vertegenwoordigd in) het influenzavaccin. Daarmee is de afwezigheid van een vroege 
lokale huidreactie in deze groep wel bruikbaar om mensen op te sporen die niet beschermd 
zijn na vaccinatie, en dus mogelijk baat zouden kunnen hebben bij een tweede vaccinatie 
(of andere maatregelen om griepinfectie te voorkomen).
In de appendix bij hoofdstuk 3 en 4 wordt onder andere het lange termijn beloop van 
de antistoftiters getoond. We zien bij mensen die met HIV geïnfecteerd zijn de antistofti-
ter na vaccinatie sneller afnemen dan in gezonde controles.
In hoofdstuk 5 kijken we naar de vorming van kruisreagerende antistoffen. Hoewel 
de antistof productie zeer specifiek is gericht tegen het vaccin-antigeen, zien we dat deze 
antistoffen ook wel enige bescherming geven tegen antigenen die erg lijken op het vaccin-
antigeen. Hier hebben we gekeken naar de influenza-antigenen die in de jaren na onze 
vaccinatie studie gingen circuleren. De antigene aanpassingen van deze virussen waren 
niet heel groot, maar groot genoeg om de vaccinsamenstelling hierop aan te passen.
Een eerdere studie liet zien dat ouderen slecht in staat waren kruisreagerende antistof-
fen te produceren. Daarmee kan een vaccin falen als de vaccinstam in een bepaald jaar 
niet geheel overeen blijkt te komen met de ‘epidemische stam’ die uiteindelijk dat seizoen 
circuleert. Zo’n ‘mismatch’ kan zo nu en dan optreden omdat de vaccinstammen ruime 
tijd van te voren gekozen moeten worden. In de tussentijd kan een griepvirus zich verder 
evolueren waardoor het niet meer (geheel) overeenkomt met de gekozen vaccinstam.
Het onvermogen om breder kruisreagerende antistoffen te produceren, zoals gevonden 
bij ouderen, werd niet gevonden bij mensen die geïnfecteerd zijn met HIV. Zij zullen, 
ook als er een beperkte ‘mismatch’ is tussen de vaccinstam en het circulerende virus, wel 









































In hoofdstuk 6 vervolgen we een cohort van 30 HIV-geïnfecteerden over langere tijd. 
Zij werden geïncludeerd in een rabiës (hondsdolheid) vaccinatie studie, nadat ze gemid-
deld 41 maanden behandeld waren met HIV-remmers. Velen van hen hadden een ernstig 
verminderde afweer op het moment (rond 1996) dat zij met HIV-remmers begonnen. 
Door de HIV-behandeling was bij iedereen het aantal CD4-positieve T-lymfocyten weer 
tot normale waarden hersteld op het moment van vaccinatie. Door een neo-antigeen te 
gebruiken (een antigeen dat het immuunstelsel niet eerder heeft gezien) konden we testen 
of deze nieuw gevormde CD4-cellen ook functioneel in staat waren ‘normaal’ bij te dragen 
aan de immuunrespons. We bekeken drie aspecten van de afweerreactie die afhankelijk 
zijn van CD4-cellen. Het bleek dat al deze processen weliswaar weer functioneerde maar 
altijd nog minder dan bij gezonde controles.
Vijf jaar na de rabiës vaccinatie bleek tweederde van de HIV-geïnfecteerden nog steeds 
beschermd tegen hondsdolheid.
Hoofdstuk 7 is een overzichtsartikel over vaccinaties bij mensen die geïnfecteerd zijn 
met HIV. Het bevat onder andere de gecombineerde data van de studie beschreven in 
hoofdstuk 4; een tabel met praktische adviezen en commentaar op de recente ‘Mexicaanse 
griep’ vaccinatie campagne.
dIscussIe
De studies beschreven in dit proefschrift geven een beeld van verschillende aspecten van 
de afweer bij een aantal groepen immuungecompromitteerden. Daarmee dragen deze 
studies bij aan het begrip van het werkingsmechanisme van immuunsuppressiva en de 
functionaliteit van de afweer bij mensen die geïnfecteerd zijn met HIV.
Hoewel de studies voortkwamen uit praktische vragen van onszelf en andere clinici, 
zijn er meer antwoorden gevonden dan alleen het antwoord op die vragen (bijvoorbeeld: 
‘Is het zinvol om iemand die met anti-TNF behandeld wordt de griepprik te geven?’). 
Maar zoals aangegeven in één van de stellingen, het onderzoek roept ook weer veel vragen 
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te starten (opleider dr. J.C.M. van der Vijver), een opleiding die 6 jaar later in Leiden werd 
afgerond (opleider prof. dr. A.E. Meinders). Weer een jaar later registreerde hij zich als 
internist-infectioloog (opleider prof. dr. J.T. van Dissel). Tot 2007 bleef hij aan de afdeling 
infectieziekten van het Leids Universitair Medisch Centrum verbonden om zich bezig te 
houden met de academische trias (onderzoek, klinische werkzaamheden en onderwijs). 
De onderzoeken beschreven in dit proefschrift zijn in die tijd zijn opgestart en uitgevoerd.
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